



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

Fiche

009614

OFFICE OF  
PESTICIDES AND TOXIC  
SUBSTANCES

JUL 22 1992

MEMORANDUM

SUBJECT: Glyphosate - List A Chemical for Reregistration -  
Rereview of Toxicology Studies for Acceptability

Caswell No.: 661A  
Project No.: 1-0904  
ID No.: 103601  
Task Hours: 488

FROM: William Dykstra, Ph.D. *William Dykstra 5/31/91*  
Review Section I  
Toxicology Branch I - Insecticide, Rodenticide Support  
Health Effects Division (H7509C)

TO: Jay Ellenberger, PM 50  
Reregistration Branch  
Special Review and Reregistration Division (H7508C)

*for* THRU: Roger L. Gardner, Section Head *Pamela M. Hurley 5/14/91*  
Review Section I  
Toxicology Branch I - Insecticide, Rodenticide Support  
Health Effects Division (H7509C)

*R. G. 7/15/92*

Requested Action

The following studies need to be rereviewed to determine their acceptability: 81-1; 81-2; 82-2; 83-1a; 83-3a; 83-3b; 83-4; 84-2a; 84-2b; and 84-4 (other genotoxic effects).

Reviewed By: William Dykstra, Ph.D. *William Dykstra 6/11/91*  
Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Roger Gardner 5/14/91*  
Toxicology Branch I - IRS (H7509C)

009614

DATA EVALUATION REPORT

Study Type: 84-2(b); Cytogenetics In Vivo TOX Chem. No.: 661A

Accession No.: 251737

MRID No.: 00132683

Test Material: Glyphosate Technical; 98.7% Purity

Synonyms: EHL Sample No. T2830044

Study Number: ML-83-236

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: Environmental Health Lab, St. Louis, MO

Title of Report: In Vivo Bone Marrow Cytogenetics Study of  
Glyphosate in Sprague-Dawley Rats.

Author: A.P. Li

Report Issued: October 20, 1983

Conclusions:

Glyphosate did not induce significant clastogenic effects in rats under conditions of the study which was limited to the assay of a single dose level of 1000 mg/kg. Cylcphosphamide at 25 mg/kg caused a highly significant number of chromosomal aberrations demonstrating the sensitivity of the assay. Under the conditions of the study, glyphosate did not cause any fatalities or other signs of toxicity. Monsanto addressed previous issues in the letter of November 26, 1984 (memorandum of W. Dykstra of March 12, 1985, attached).

Classification: Acceptable

Special Review Criteria (40 CFR 154.7): N/A

Note: Dr. Irving Mauer, geneticist, screened this mutagenicity study for acceptability. The DER is based on part of a Dynamac review.

00006

009614

Review:

Quality Assurance Statement - Present and dated October 21, 1983.

Test Material - The test material was identified as glyphosate (EHL Sample No. TA830044), a white powder having a purity of 98.7 percent.

Materials and Methods:

Preparation of Test Material - The test material was suspended in Hank's buffered salt solution (HBSS) at a concentration of 100 mg/mL and was neutralized to pH 7.0. Solutions were prepared no more than 24 hours before use. A volume of 10 mL/kg was used for ip dosing.

Controls - Cyclophosphamide, the positive control, was dissolved in HBSS (25 mg/mL). One mL/kg (25 mg/kg) was used for dosing. A volume of 10 mL/kg HBSS, the solvent control, was administered intraperitoneally (ip) to the control animals.

Animals - The animals used in the study were male and female Sprague-Dawley rats [CD(SD)BR] from Charles River Breeding Laboratories, which were approximately 9 weeks old at the time of dosing. Water and Purina Laboratory Chow were provided ad libitum except at the fasting period 14 to 24 hours prior to dosing. Animals were maintained in individual cages in rooms maintained at 70 to 74 °F, a relative humidity of 35 to 60 percent, and on a 12-hour light/dark cycle.

Experimental Design - Rats (18/sex/group) were fasted for 14 to 24 hours and then injected ip with (i) solvent (HBSS), (ii) glyphosate (1 g/kg), or (iii) cyclophosphamide (25 mg/kg). Six animals of each sex and group (control, test group, and positive control group) were sacrificed at 6, 12, and 24 hours. Two hours before sacrifice each rat was injected ip with 2 mg/kg colchicine. Sacrifice was by CO<sub>2</sub> asphyxiation and spinal cord severance.

Preparation of Bone Marrow Cells - Marrow was aspirated from each femur into a 5 mL syringe containing 2 mL HBSS. The contents were added to 5 mL of HBSS in a plastic centrifuge and maintained at 37 °C until the slides were prepared.

Slide Preparation - The cells were pelleted by centrifugation (700 x g, 10 min), suspended in 1 mL of hypotonic KCl (0.075 M), and incubated at 37 °C for 30 minutes. The cells were then fixed with an equal volume of Corney's solvent (3/1, v/v methanol glacial acetic acid). The pellet was resuspended in 4 mL of fresh cold fixative and one to two drops of each suspension placed on a clean wet slide. The slides were air dried, stained for 15 to 20

00007

009614

minutes in a 2 percent Giesma solution, rinsed with water, and again air dried.

Scoring of Slides - The slides were scored by three persons in Dr. Julian Preston's laboratory (Oak Ridge National Laboratory). Approximately 50 mitotic cells (300/treatment) were scored for chromosomal aberrations. The following data were recorded:

Number of cells scored  
 Number of cells with normal chromosome numbers  
 Chromosome-type aberrations (dicentric, ring, deletions)  
 Chromatid-type aberrations (chromatid deletions, isochromatid deletions, interchanges, intrachanges)  
 Achromatic lesions (gaps)  
 Number of aneuploid cells  
 Location of cells with aberrations

Statistical Analysis - The Student's t-test was used for data analysis, in which dosing with the test material or positive control was compared to the solvent control.

#### Results:

The frequency of chromatid-type aberrations was low in both solvent control and glyphosate treated groups (Table 1).

Table 1. Chromatid-Type Aberrations

| Time     | Control            | Glyphosate |
|----------|--------------------|------------|
| 6 hours  | 7/588 <sup>a</sup> | 6/544      |
| 12 hours | 2/588 <sup>a</sup> | 5/564      |
| 24 hours | 4/555 <sup>a</sup> | 7/479      |

<sup>a</sup>Number of aberrations/number of mitotic cells examined. Data for males and females was combined by this reviewer.

There were no chromosomal-type aberrations in marrow cells in either solvent controls or the glyphosate group.

The positive control group was scored only at 24 hours. Because of extreme cytotoxicity, only 21 cells were available for scoring in females and 256 cells in males. There was a high incidence of chromatid type aberrations (231/277 chromatid deletions, 71/231 chromatid interchanges, and 6/277 chromatid intrachanges).

00008



Conclusions and Recommendations

New DER's are attached for each of the studies which have been rereviewed for acceptability. The results of the rereview are summarized below.

Technical Glyphosate

| <u>Study</u>   | <u>Results</u>                                                                        | <u>Classification<br/>(Core-Grade)</u> |
|----------------|---------------------------------------------------------------------------------------|----------------------------------------|
| 81-1           | Toxicity Category III                                                                 | Minimum                                |
| 81-2           | Toxicity Category IV                                                                  | Minimum                                |
| 82-2           | NOEL = 1000 mg/kg/day                                                                 | Guideline                              |
| 83-1a          | NOEL = 31 mg/kg/day                                                                   | Minimum                                |
| 83-3a (Rats)   | Negative for Terata:<br>Developmental NOEL = 1000 mg/kg<br>Maternal NOEL = 1000 mg/kg | Guideline                              |
| 83-3b (Rabbit) | Negative for Terata:<br>Developmental NOEL = 350 mg/kg<br>Maternal NOEL = 175 mg/kg   | Minimum                                |
| 83-4           | NOEL = 10 mg/kg/day                                                                   | Minimum                                |
| 84-2a          | Negative for HGPRT/CHO                                                                | Acceptable                             |
| 84-2b          | Negative for <u>in vivo</u> Rat<br>Cytogenetics                                       | Acceptable                             |
| 84-2a          | Negative for Ames Assay<br>(Two studies)                                              | Acceptable                             |
| 84-2b          | Negative for Mouse Dominant<br>Lethal                                                 | Unacceptable                           |
| 84-4           | Negative for Rec-Assay in<br><u>B. subtilis</u>                                       | Acceptable                             |
| 84-4           | Negative for DNA Repair in Rat<br>Hepatocytes                                         | Unacceptable                           |

C09614

Reviewed by: William Dykstra, Ph.D. *William Dykstra 4/9/91*  
Review Section I, Toxicology Branch I (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Annella M. Hurley 5/4/91*  
Review Section I, Toxicology Branch I (H7509C)

DATA EVALUATION REPORT

Study Type: 81-1, Acute oral, rats TOX Chem No. 661A  
MRID No.: 00067039

Accession Number: N/A

Test Material: Glyphosate, technical; sample No. 96

Synonyms: Roundup, Rodeo, Polado; CP67573-3

Study Number: Monsanto Project No. Y-70-90

Sponsor: Monsanto Company  
St. Louis, MO 63129

Testing Facility: Younger Laboratories  
St. Louis, MO

Title of Report: Toxicological Investigation of: CP67573-3

Author: Melvin D. Birch

Report Issued: September 18, 1970

Conclusion: The test material was prepared as a 25.0% aqueous solution-suspension. Four groups of male and female (a total of 5 rats/group) Sprague-Dawley young rats received single, oral doses by gavage of 3160, 3980, 5010 and 6310 mg/kg of test material. Observation was for 7 days. Mortality was 1/5, 2/5, 3/5 and 5/5 for the four groups.

LD<sub>50</sub> (Both sexes) = 4320 mg/kg (3930 - 4750 mg/kg)

Classification: Core-Minimum Toxicity Category III

Special Review Criteria: (40 CFR 154.7) N/A

00003

009614

Review

1. Acute Oral, Rat: Toxicological Investigation of: CP67573-3  
(Younger Laboratories, Melvin D. Birch, 9/18/70)

Test Material: glyphosate, technical; Sample No. 96

The test material was prepared as a 25.0% aqueous solution-suspension. Four groups of male and female (a total of 5 rats per group) young Sprague-Dawley rat received single, oral doses by gavage of 3160, 3980, 5010 and 6310 mg/kg of test material. Observation was for seven days.

Results: LD<sub>50</sub> (Both sexes) = 4320 mg/kg; 95% C.L. (3930-4750 mg/kg) Method of E.J. deBeer for LD<sub>50</sub>

As shown below, mortality was 1/5, 2/5, 3/5 and 5/5

**THE ORAL LD<sub>50</sub> OF 'CP 67573-3' FOR RATS**

Sample Fed As A 25.0% Aqueous Solution-Suspension

| <u>Animal No. - Sex</u> | <u>Weight<br/>Grams</u> | <u>Dose<br/>Mg./Kg.</u> | <u>Fate</u> |
|-------------------------|-------------------------|-------------------------|-------------|
| 1 - Female              | 225                     | 3160                    | Survived    |
| 2 - Male                | 200                     | 3160                    | Survived    |
| 3 - Female              | 200                     | 3160                    | Died        |
| 4 - Male                | 210                     | 3160                    | Survived    |
| 5 - Female              | 205                     | 3160                    | Survived    |
| 6 - Male                | 200                     | 3980                    | Survived    |
| 7 - Female              | 215                     | 3980                    | Died        |
| 8 - Male                | 220                     | 3980                    | Survived    |
| 9 - Female              | 195                     | 3980                    | Survived    |
| 10 - Male               | 205                     | 3980                    | Died        |
| 11 - Female             | 200                     | 5010                    | Died        |
| 12 - Male               | 200                     | 5010                    | Survived    |
| 13 - Female             | 190                     | 5010                    | Died        |
| 14 - Male               | 200                     | 5010                    | Died        |
| 15 - Female             | 200                     | 5010                    | Survived    |
| 16 - Male               | 215                     | 6310                    | Died        |
| 17 - Female             | 205                     | 6310                    | Died        |
| 18 - Male               | 215                     | 6310                    | Died        |
| 19 - Female             | 200                     | 6310                    | Died        |
| 20 - Male               | 235                     | 6310                    | Died        |

Survival Time: Several hours to six days

Toxic Signs: Reduced activity and reduced appetite (three to seven days in survivors), lethargy, diarrhea, increasing weakness,

00004

009614

collapse and death.

Necropsy: Hemorrhagic lungs and liver and gastrointestinal inflammation (acute in some cases).

Comment: There were no signed statements of Quality assurance or GLP's. However, the report was signed by Melvin D. Birch of the testing lab. Although this study does not fulfill all details of a Subpart F (1982), 81-1, Guidelines Study, the compound, glyphosate, based on mortality data in this study, falls clearly within Toxicity Category III

Classification: Core-Minimum

00005

009614

Reviewed by: William Dykstra, Ph.D. *William Dykstra 4/9/91*  
Section I, Tox. Branch I, IRS, H7509C  
Secondary reviewer: Roger Gardner, Section Head *Rhonda M. Hurley 5/14/91*  
Section I, Tox. Branch I, IRS, H7509C

DATA EVALUATION REPORT

STUDY TYPE: 81-2, Acute Dermal, Rabbits TOX. CHEM.NO. 661A

ACCESSION NUMBER: N/A MRID NO. 00067039

TEST MATERIAL: Glyphosate, Technical; sample 96

SYNONYMS: CP 67573-3; Roundup.

STUDY NUMBER (s): Monsanto Project No. Y-70-90

SPONSOR: Monsanto Co., St. Louis, MO

TESTING FACILITY: Younger Laboratories, St. Louis, MO

TITLE OF REPORT: Toxicological Investigation of CP-67573-3

AUTHORS (s): Melvin D. Birch

REPORT ISSUED: 9/18/70

CONCLUSIONS: LD<sub>50</sub> > 7940 mg/kg (females) and 5010 mg/kg (males)

Two NZW rabbits, one male and one female, were used in the study.

One male young NZW, 1.8 kg BW, received a dermally applied dose of 5010 mg/kg of glyphosate technical, as a 50% aqueous paste, on the fur clipped trunk under occlusive wrap for 24 hours. One NZW young female rabbit, 1.8 kg BW received 7940 mg/kg under similar occlusion for 24 hours.

There were no deaths in the study during the 14 day observation period. There were no clinical signs and no abnormal necropsy findings.

Although there are obviously insufficient numbers of rabbits used, technical glyphosate is clearly in toxicity category IV and would undoubtedly exceed the 2.0 mg/kg limit dose for dermal toxicity guidelines.

Classification: Core-minimum Toxicity Category IV

00000

009814

Review

1. Acute Dermal LD<sub>50</sub> - Rabbits (Toxicological Investigations of CP 67573-3; Younger Laboratories; Monsanto Project No. Y-70-90; 9/18/70)

Test Material: glyphosate, technical; Sample No. 96

Two NZW rabbits, one male and one female, were used in the study. The male rabbit and female rabbit each weighed 1.8 kg BW. The male and female rabbits received, as a 50.0 % aqueous paste, dermally applied doses of technical glyphosate (male rabbit received 5010 mg/kg and female rabbit received 7940 mg/kg) on the fur clipped trunk under an occlusive wrap for 24 hours. Observations were for 14 days. Lack of sample prevented further testing.

Results: There were no deaths.

LD<sub>50</sub> > 7940 mg/kg (female)

LD<sub>50</sub> > 5010 mg/kg (male)

These results are shown below as presented in the report:

Sample Applied As A 50.0% Aqueous Suspension

| <u>Animal No. - Sex</u> | <u>Weight<br/>Kg.</u> | <u>Dose<br/>Mg./Kg.</u> | <u>Weight Change<br/>5 Days Later<br/>/Kg.</u> | <u>Fate</u> |
|-------------------------|-----------------------|-------------------------|------------------------------------------------|-------------|
| 1 Male                  | 1.8                   | 5010                    | 0.1                                            | Survived    |
| 2 Female                | 1.8                   | 7940                    | 0.0                                            | Survived    |

Toxic Signs: None observed

Necropsy: No abnormal findings reported

Classification: Core-Minimum Toxicity Category IV

00007

009614

Disk 3 HES TC661C

00003

009614

Reviewed by: William Dykstra, Ph.D. *William Dykstra 5/14/91*  
Section I, Tox. Branch I, IRS, H7509C  
Secondary reviewer: Roger Gardner, Section Head *Pamela M. Hanley 5/14/91*  
Section I, Tox. Branch I, IRS, H7509C

DATA EVALUATION REPORT

**STUDY TYPE:** 82-2, 21 Day Dermal, Rabbit **TOX. CHEM. NO.:** 661A  
**MRID No.** 00098460

**ACCESSION NUMBER:** N/A

**TEST MATERIAL:** glyphosate technical, white powder

**SYNONYMS:** Roundup, Rodeo, Polado

**STUDY NUMBER(s):** IRDC, No. 401-168

**SPONSOR:** Monsanto Co., St. Louis, MO

**TESTING FACILITY:** IRDC, Mattawan, MI

**TITLE OF REPORT:** 21-day dermal toxicity study in rabbits

**AUTHOR(s):** Dale E. Johnson, Study Director, 3/16/82

**REPORT ISSUED:** March 10, 1982

Technical glyphosate was tested in a 21-day dermal study in rabbits at the following dose levels: 0, 100, 1000 and 5000 mg/kg/day both with intact and abraded skin.

**CONCLUSIONS:** The NOEL is 1000 mg/kg/day (mid-dose). The LEL is 5000 mg/kg/day and the effects were (1) very slight erythema and edema observed visually, but not microscopically, in both sexes of intact and abraded skin of treated rabbits in comparison to controls; (2) food consumption was consistently decreased in two female high-dose rabbits during the study to a greater extent than in controls and (3) LDH was statistically significantly decreased in both sexes at the high-dose, but this was not considered a toxicologically significant finding (Clinical Guide to Laboratory Tests, N.W. Tietz, 1983, W.B. Saunders Co.).

**Classification:** Core-guideline

**Testing Guideline Satisfied:** 82-2

00039



009614

Review

1. 21-day dermal toxicity study in rabbits (IRDC No. 401-168; 3/10/82)

Test Material: glyphosate, technical; white powder; purity not given; source: Monsanto Company.

Quality Assurance Statement: Signed by Barry W. Benson, B.S., Director of Quality Assurance, March 10, 1982. In addition, a statement was provided by the Study Director that GLP's were followed.

Animals: Sixty-two male and 62 female NFW rabbits, young adults, were purchased from Davidson's Mill Farm, Jamesburg, N.J. and were acclimated to the IRDC laboratory for 14 to 16 days prior to initiation of the study.

Rabbits were individually housed and fed Purina Certified Rabbit Chow #5322 and water ad libitum. Animals were observed daily and placed into study groups based upon sex and body weight and randomized selection.

Methods Forty male (2359-2883g) and forty female (2344-2955g) rabbits were assigned to the following treatment groups

| Group                                       | Test Material     | Dose Level<br>Mg/kg | Number of animals and skin preparation |   |        |   |
|---------------------------------------------|-------------------|---------------------|----------------------------------------|---|--------|---|
|                                             |                   |                     | Male                                   |   | Female |   |
|                                             |                   |                     | I                                      | A | I      | A |
| I                                           | control           | 0                   | 5                                      | 5 | 5      | 5 |
| II                                          | glyphosate, tech. | 100                 | 5                                      | 5 | 5      | 5 |
| III                                         | glyphosate, tech. | 1000                | 5                                      | 5 | 5      | 5 |
| IV                                          | glyphosate, tech. | 5000                | 5                                      | 5 | 5      | 5 |
| I - Intact                      A - Abraded |                   |                     |                                        |   |        |   |

Approximately 30% of the body surface of the trunk of each rabbit was shaved free of hair to begin the study and as often as needed. Twice each week, immediately prior to administration of the test material, the dorsal skin of one-half of the rabbits was abraded.

The test material was moistened (made pasty) with physiological saline and evenly applied onto the shaved skin surface of the rabbits. The test material was held in place by occlusion for six hours per day, five days per week for 3 consecutive weeks. The test material was washed off after each 6 hour exposure period. The rabbits wore collars to avoid ingestion of the test material during the entire study.

00010

009614

**Observations:****1. Toxic Signs and skin Reaction**

The rabbits were observed once daily for toxic signs and skin reaction.

**Results** - There were no compound-related signs of systemic toxicity. Dermal irritation, consisting of slight erythema and edema, was observed. Scores of 0.5 for edema and erythema in intact skin and scores of 0.5 to 1.0 for edema and erythema in abraded skin were observed at 5000 mg/kg/day. These outwardly observable skin reactions were not detected microscopically. There was no dermal irritation at 100 or 1000 mg/kg/day.

**2. Mortality** - Rabbits were observed twice daily for mortality.

**Results:** There were no deaths during the study.

**3. Body Weight** - Body weights were obtained twice weekly during the study.

**Results:** There were no statistically significant changes in body weight or body weight gain in treated male and female intact or abraded rabbits in comparison to controls. The following tables, taken from the report, show the body weight changes in intact and abraded rabbits

| Means, Standard Deviations, N and Significance<br>Body Weight Changes (grams), Abraded |                   |       |           |       |            |       |            |       |
|----------------------------------------------------------------------------------------|-------------------|-------|-----------|-------|------------|-------|------------|-------|
| Study Period                                                                           | 0 mg/kg (Control) |       | 100 mg/kg |       | 1000 mg/kg |       | 5000 mg/kg |       |
|                                                                                        | M                 | F     | M         | F     | M          | F     | M          | F     |
| Initiation - Term                                                                      |                   |       |           |       |            |       |            |       |
| Ave.                                                                                   | 298               | 353   | 207       | 299   | 535        | 520   | 356        | 338   |
| S.D.                                                                                   | 236.1             | 306.8 | 179.0     | 275.9 | 202.6      | 279.2 | 187.7      | 305.1 |
| N                                                                                      | 5                 | 5     | 5         | 5     | 5          | 5     | 5          | 5     |

| Means, Standard Deviations, N and Significance<br>Body Weight Changes (grams), Intact |                   |       |           |       |            |       |            |       |
|---------------------------------------------------------------------------------------|-------------------|-------|-----------|-------|------------|-------|------------|-------|
| Study Period                                                                          | 0 mg/kg (Control) |       | 100 mg/kg |       | 1000 mg/kg |       | 5000 mg/kg |       |
|                                                                                       | M                 | F     | M         | F     | M          | F     | M          | F     |
| Initiation - Term                                                                     |                   |       |           |       |            |       |            |       |
| Ave.                                                                                  | 341               | 410   | 281       | 154   | 409        | 354   | 177        | 237   |
| S.D.                                                                                  | 146.2             | 110.1 | 114.1     | 239.3 | 187.2      | 218.0 | 110.6      | 482.6 |
| N                                                                                     | 5                 | 5     | 5         | 5     | 5          | 5     | 5          | 5     |

00011

009614

4. Food Consumption - Visual estimates of food consumption were made daily for each rabbit.

Results: Although decreases (and some increases) were randomly noted in all groups on several occasions, there did appear to be a treatment-related effect in decreased food consumption in treated females at 5000 mg/kg in comparison to controls. At 5000 mg/kg/day intact skin, treated females had consistently lower food consumption in two rabbits (#14390 and 14428) in comparison to controls.

5. Clinical Pathology Studies - Blood was collected from the ear vein of each rabbit at day 21 for evaluation of hematology and clinical chemistry studies.

a. Hematology -

| X |                          | X |                                   |
|---|--------------------------|---|-----------------------------------|
| X | Hematocrit (HCT)*        |   | Total plasma protein (TP)         |
| X | Hemoglobin (HGB)*        | X | Leukocyte differential count      |
| X | Leukocyte count (WBC)*   | X | Mean corpuscular HGB (MCH)        |
| X | Erythrocyte count (RBC)* | X | Mean corpuscular HGB conc. (MCHC) |
| X | Platelet count*          | X | Mean corpuscular volume (MCV)     |
| X | Reticulocyte count       |   |                                   |

Results - There were no dose-related, statistically significant differences between control and treated male and female rabbits. Although occasional statistically significant findings did occur, based on their lack of dose-response, they were not considered compound-related. Therefore, there were no compound-related hematological findings in treated male and female rabbits in comparison to controls.

00012

009614

b. Clinical Chemistry

| X Electrolytes: |                                               | X Other: |                      |
|-----------------|-----------------------------------------------|----------|----------------------|
| X               | Calcium*                                      | X        | Albumin*             |
| X               | Chloride*                                     | X        | Blood creatinine*    |
|                 | Magnesium*                                    | X        | Blood urea nitrogen* |
| X               | Phosphorous*                                  | X        | Cholesterol*         |
| X               | Potassium*                                    | X        | Globulins            |
| X               | Sodium*                                       | X        | Glucose*             |
| Enzymes         |                                               | X        | Total Bilirubin*     |
| X               | Alkaline phosphatase                          | X        | Total Protein*       |
|                 | Cholinesterase                                |          | Triglycerides        |
|                 | Creatinine phosphokinase*                     |          |                      |
| X               | Lactic acid dehydrogenase                     |          |                      |
| X               | Serum alanine aminotransferase (also SGPT)*   |          |                      |
| X               | Serum aspartate aminotransferase (also SGOT)* |          |                      |

Results - Lactate dehydrogenase (LDH) was significantly reduced in high-dose males and females in comparison to controls. The values (IU/L) were 250, 169, 291 and 76\* for C, L, M and HD males and 189, 149, 258 and 28\* for C, L, M. and HD females (\*P<0.05). However, decreases in lactate dehydrogenase are not of toxicological significance. Therefore, there were no compound-related, toxicologically significant findings in clinical chemistries in treated males and females in comparison to control. Other statistically significant findings were also not considered toxicologically significant.

6. Sacrifice and Pathology -

All animals that died and that were sacrificed on schedule were subject to gross pathological examination and they were CHECKED (X) tissues were collected for histological examination. The (XX) organ in addition were weighed.

009614

|    |                  |    |                    |   |                              |
|----|------------------|----|--------------------|---|------------------------------|
| X  |                  | X  |                    | X |                              |
|    | Digestive system |    | Cardiovasc./Hemat. |   | Neurologic                   |
|    | Tongue           |    | Aorta*             |   | Brain*                       |
|    | Salivary glands* | W  | Heart*             |   | Periph. nerve*               |
|    | Esophagus*       |    | Bone marrow*       |   | Spinal cord (3 levels)*      |
|    | Stomach*         |    | Lymph nodes*       | W | Pituitary*                   |
|    | Duodenum*        |    | Spleen*            |   | Eyes (optic n.)*             |
|    | Jejunum*         |    | Thymus*            |   | Glandular                    |
|    | Ileum*           |    | Urogenital         | W | Adrenals*                    |
|    | Cecum*           | XX | Kidneys*           |   | Lacrimal gland               |
|    | Colon*           |    | Urinary bladder*   |   | Mammary gland*               |
|    | Rectum*          | XX | Testes*            | W | Parathyroids*                |
| XX | Liver*           | X  | Epididymides       | W | Thyroids*                    |
|    | Gall bladder*    |    | Prostate           |   | Other                        |
|    | Pancreas*        |    | Seminal vesicle    |   | Bone*                        |
|    | Respiratory      | XX | Ovaries            |   | Skeletal Muscle*             |
|    | Trachea*         | X  | Uterus*            | X | Skin (treated & untreated)   |
|    | Lung*            |    |                    | X | All gross lesions and masses |

W: Weighed but not examined microscopically.

00014

009614

### Results

#### a. Organ weight -

There were no statistically significant differences between absolute and relative organ weights of male and female treated rabbits in comparison to controls.

#### b. Gross pathology -

There were no compound-related macroscopic observations in treated male and female rabbits in comparison to controls. The findings which were observed occurred in control as well as treated groups and were not dose-related. Most findings occurred as single animal observations.

#### c. Microscopic pathology -

##### 1) Non-neoplastic

No compound-related microscopic lesions were observed in treated male and female tissues examined in comparison to controls, including treated and untreated skin from both sexes. The findings which did occur were not dose-related. In treated skin and untreated skin, the most common finding with respect to incidence and grade was trace to mild dermal inflammatory cell infiltrate. Although, one mid-dose female had trace necrosis in treated skin, untreated skins of 3 male rabbits from the mid-dose and one from the high-dose also showed mild focal necrosis. Therefore, this finding was not compound-related. Additionally, testes of male rabbits from the control and test groups showed trace to mild seminiferous tubule degeneration. This was not compound-related but probably due to non-specific stress.

7. Statistics: Body weights (terminal), hematological and biochemical parameters (day 21) and absolute and relative organ weights (terminal sacrifice) were compared by analysis of variance (one-way classification), Bartlett's test for homogeneity of variances and the appropriate c-test (for equal or unequal variances) as described by Steel and Torrie using Dunnett's multiple comparison tables to judge significance of differences.

All statistical analyses compared the treatment groups with the control groups, by sex.

00015

009614

Disk 4 HES Rabbit66.1A

00016

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/13/81*  
Section I, Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Pamela M. Henley 5/13/91*  
Section I, Toxicology Branch I - IRS (H7509C) *R. G. 7/2/91*

DATA EVALUATION REPORT

009614

Study Type: 83-1, Chronic Toxicity - Rat TOX Chem. No.: 661A

Accession Number: MRID No.: 00093879

Test Material: Glyphosate, technical; 98.7% purity; Lot XHJ-64;  
white powder

Synonyms: Roundup

Study Number: Bio/Dynamics, Inc., Project No. 77-2062

Sponsor: Monsanto Company

Testing Facility: Bio/Dynamics, Inc.  
East Millstone, NJ

Title of Report: A Lifetime Feeding Study of Glyphosate in Rats.

Authors: George P. Lankas, Study Director, December 15, 1981

Report Issued: December 23, 1981

Conclusions:

Male and female rats were fed glyphosate in the diet for 26 months at the following dose levels: 0, 3, 10, and 31 mg/kg/day.

The NOEL for chronic toxicity was 31 mg/kg/day (HDT). There was no MTD in the study and therefore the study does not qualify as a carcinogenicity study. Nevertheless, oncogenic issues relating to C-cell thyroid carcinomas in females and interstitial cell testicular tumors were observed and have been fully addressed. The carcinogenic potential was negative up to 31 mg/kg/day (HDT).

Classification: Core-Minimum (for chronic toxicity only)

Special Review Criteria (40 CFR 154.7): N/A

00017



009614

A. Materials:

1. Test Compound - Glyphosate, technical; Description: white powder; Batch No.: XHJ-64; Purity: 98.7 percent; Contaminants: List in CBI appendix.
2. Test Animals - Species: Albino Rat; Strain: Sprague-Dawley CD; Age: 28 days; Weight - Males: 124 g, Females: 102 g; Source: Charles River, Wilmington, MA 01887.

B. Study Design:

1. Animal Assignment - Animals were assigned randomly to the following test groups:

| Test Group   | Dose in Diet<br>(mg/kg/day) | Main Study<br>26 Months |        | Interim Sacrifice<br>Months |        |
|--------------|-----------------------------|-------------------------|--------|-----------------------------|--------|
|              |                             | Male                    | Female | Male                        | Female |
| 1 Control    | 0                           | 50                      | 50     | --                          | --     |
| 2 Low (LDT)  | 3                           | 50                      | 50     | --                          | --     |
| 3 Mid (MDT)  | 10                          | 50                      | 50     | --                          | --     |
| 4 High (HDT) | 31                          | 50                      | 50     | --                          | --     |

2. Diet Preparation - Diet was prepared weekly and stored at room temperature. Samples of treated food were analyzed for stability and concentration at day 1 and day 7 of each feed preparation.

Results - Diet analyses results show analytical levels were within + 16 percent of nominal concentrations for all three dose levels during the entire study. Additionally, glyphosate was stable in the basal diet for the 1-week period of use with assays ranging from 97.4 to 116 percent with a mean value of 104 percent.

Homogeneity analyses of the top, middle, and bottom of the 30, 100, and 300 ppm diets showed the percents of planned diet averaged 95.8, 97.0, and 99.9 percent, respectively. The coefficients of variation were less than 6.3 percent for each dose level measurement.

3. Animals received food (Purina Lab Chow) and water ad libitum.
4. Statistics - Body weight, food consumption, hematology and clinical chemistry parameters, organ weights and organ/body weight ratios, and organ/brain weight ratios were analyzed. Mean values of all dose groups were compared to control at each time interval. Statistically significant differences from control were set at  $p < 0.05$ . Statistical methods are attached (Appendix A).

009614

5. Quality assurance was signed by Craig Lamb on September 23, 1981.

C. Methods and Results:

1. Observations - Animals were inspected twice daily for signs of toxicity and mortality and weekly for detailed physical examination.

There were no compound-related toxic signs. The most frequent observations were alopecia, lacrimation, nasal discharge, and rales and occurred at comparable frequencies between control and treated rats of both sexes.

Results

Mortality (Survival) - Survival was approximately 80 to 90 percent through month 20. The study was terminated at month 26 when survival reached 30 percent in control males and high-dose females. The following Table from the report summarizes survival results.

|                    |                        | Mortality <sup>a</sup> |                   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |       |
|--------------------|------------------------|------------------------|-------------------|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-------|
| Group<br>mg/kg/day | Initial No.<br>on Test | Month:                 | Number of Animals |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |       |
|                    |                        |                        | 1                 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | Total |
| Males              |                        |                        |                   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |       |
| I<br>0.00          | 50                     |                        | 0                 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0  | 0  | 0  | 0  | 0  | 0  | 2  | 1  | 2  | 1  | 4  | 4  | 1  | 8  | 2  | 4  | 3  | 35    |
| II<br>3.05         | 50                     |                        | 0                 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0  | 0  | 1  | 0  | 1  | 0  | 0  | 2  | 0  | 2  | 1  | 2  | 7  | 5  | 2  | 0  | 24 |       |
| III<br>10.30       | 50                     |                        | 0                 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0  | 0  | 0  | 0  | 0  | 2  | 0  | 0  | 1  | 0  | 1  | 4  | 3  | 5  | 8  | 4  | 3  | 34    |
| IV<br>31.45        | 50                     |                        | 0                 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0  | 0  | 0  | 0  | 0  | 1  | 0  | 0  | 0  | 1  | 5  | 2  | 4  | 4  | 6  | 1  | 24 |       |
| Females            |                        |                        |                   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |       |
| I<br>0.00          | 50                     |                        | 0                 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0  | 0  | 1  | 0  | 0  | 1  | 0  | 1  | 1  | 0  | 4  | 2  | 11 | 3  | 5  | 3  | 32 |       |
| II<br>3.37         | 50                     |                        | 0                 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0  | 0  | 0  | 0  | 0  | 2  | 1  | 0  | 0  | 2  | 2  | 6  | 0  | 5  | 7  | 1  | 27 |       |
| III<br>11.22       | 50                     |                        | 0                 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0  | 0  | 2  | 0  | 1  | 0  | 0  | 0  | 2  | 1  | 4  | 1  | 5  | 2  | 2  | 0  | 22 |       |
| IV<br>34.02        | 50                     |                        | 0                 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1  | 0  | 0  | 0  | 0  | 1  | 0  | 4  | 3  | 2  | 3  | 4  | 6  | 1  | 6  | 3  | 35 |       |

<sup>a</sup> Includes animals dying spontaneously, accidentally, or killed in a moribund condition.

00019

009614

2. Body Weight - They were weighed weekly for 14 weeks, then biweekly for remainder of study.

### Results

| Week           | Body Weights <sup>a</sup> |                   |                   |                   |            |                   |                  |                  |
|----------------|---------------------------|-------------------|-------------------|-------------------|------------|-------------------|------------------|------------------|
|                | Males                     |                   |                   |                   | Dose (ppm) |                   |                  |                  |
|                | 0                         | 30                | 100               | 300               | 0          | 30                | 100              | 300              |
| 0              | 182+ 10                   | 182+ 13           | 183+ 11           | 183+ 12           | 141+ 10    | 138+ 8            | 139+ 9           | 137+ 9           |
| 26             | 547+ 53                   | 547+ 54<br>(100%) | 546+ 51<br>(100%) | 536+ 46<br>(98%)  | 294+ 32    | 293+ 31<br>(100%) | 288+ 28<br>(98%) | 287+ 31<br>(98%) |
| 52             | 664+ 79                   | 655+ 75<br>(99%)  | 650+ 68<br>(98%)  | 634+ 64<br>(95%)  | 366+ 57    | 356+ 51<br>(97%)  | 347+ 51<br>(95%) | 354+ 56<br>(97%) |
| 78             | 724+104                   | 725+ 96<br>(100%) | 699+ 85<br>(97%)  | 691+ 79<br>(95%)  | 427+ 94    | 404+ 71<br>(95%)  | 406+ 65<br>(95%) | 420+ 87<br>(98%) |
| 104            | 693+101                   | 689+ 88<br>(99%)  | 702+ 96<br>(101%) | 691+ 89<br>(100%) | 453+103    | 432+101<br>(95%)  | 438+ 73<br>(97%) | 444+ 83<br>(98%) |
| T <sup>c</sup> | 694+135                   | 675+113<br>(97%)  | 664+113<br>(96%)  | 692+ 94<br>(100%) | 457+127    | 456+ 91<br>(100%) | 438+ 81<br>(96%) | 448+101<br>(98%) |

<sup>a</sup> Data excerpted from submitted study. Values are mean + std. dev., calculated by the investigators.

<sup>b</sup> Percent of control, calculated by reviewer.

<sup>c</sup> T = termination, week 110 for males, 112 for females.

There were no meaningful statistically significant or dose-related decreases in body weight or decreased body weight gains during the course of the study. The maximum decreased body weight ranged 2 to 6 percent less in treated males in comparison to controls during the intermediate months of the study. For females, these differences were statistically significant during months 20 and 21, but not dose-related. These minimal differences in body weight at such a late time period (> 3 months) and the lack of effect on animal survival are considered to not be toxicologically significant.

3. Food Consumption and Compound Intake - Consumption was determined weekly for first 14 weeks and biweekly thereafter, and mean daily diet consumption was calculated. Efficiency and compound intake were calculated from the consumption and body weight gain data.

00020

009614P

Results - Food Consumption - Food consumption was comparable between control and treated rats of both sexes. Based on body weight and food consumption data, diets containing glyphosate were adjusted to achieve dietary levels of 3.05, 10.30, and 31.45 mg/kg/day in males and 3.37, 11.22, and 34.02 mg/kg/day in females.

4. Ophthalmological examinations were not performed.
5. Blood was collected before treatment and at 4, 8, 12, 18, and 24 months for hematology and clinical analysis from 10/sex/group animals. The CHECKED (X) parameters were examined.

a. Hematology

|   |                          |   |                                    |
|---|--------------------------|---|------------------------------------|
| X |                          | X |                                    |
| X | Hematocrit (HCT)*        | X | Total plasma protein (TP)          |
| X | Hemoglobin (HGB)*        | X | Leukocyte differential count       |
| X | Leukocyte count (WBC)*   |   | Mean corpuscular HGB (MCH)         |
| X | Erythrocyte count (RBC)* |   | Mean corpuscular (HGB conc. (MCHC) |
| X | Platelet count*          |   | Mean corpuscular volume (MCV)      |

b. Clinical Chemistry

|   |                                               |   |                                     |
|---|-----------------------------------------------|---|-------------------------------------|
| X | Electrolytes                                  | X | Other                               |
| X | Calcium*                                      | X | Albumin*                            |
|   | Chloride*                                     |   | Blood creatinine*                   |
|   | Magnesium*                                    | X | Blood urea nitrogen*                |
| X | Phosphorus*                                   | X | Cholesterol*                        |
| X | Potassium*                                    | X | Globulins                           |
|   | Sodium*                                       | X | Glucose* (fasting)                  |
|   | Enzymes                                       | X | Total bilirubin* & direct bilirubin |
| X | Alkaline phosphatase                          | X | Total protein*                      |
|   | Cholinesterase                                |   | Triglycerides                       |
|   | Creatinine phosphokinase*                     |   |                                     |
| X | Lactic acid dehydrogenase                     |   |                                     |
| X | Serum alanine aminotransferase (also SGPT)*   |   |                                     |
| X | Serum aspartate aminotransferase (also SGOT)* |   |                                     |

- c. Urinalysis - Urine was collected from fasted animals at 4, 12, 18, and 24 months. The CHECKED (X) parameters were examined.

---

\*Recommended by Subdivision F (October 1982) Guidelines for chronic studies.

00021

009614

|   |                         |
|---|-------------------------|
| X |                         |
| X | Appearance*             |
| X | Volume*                 |
| X | Specific gravity*       |
| X | pH                      |
| X | Sediment (microscopic)* |
| X | Protein*                |

|   |              |
|---|--------------|
| X |              |
| X | Glucose*     |
| X | Ketones*     |
| X | Bilirubin*   |
| X | Blood*       |
|   | Nitrate      |
|   | Urobilinogen |

Results - Hematological, clinical chemistries, and urinalysis evaluations at 4, 8, 12, 18, and 24 months did not indicate any compound-related effects. The occasional statistically significant finding in a parameter was either not dose-related, within the range of historical controls, not consistently occurring over time, or was without toxicological significance.

7. Sacrifice and Pathology - All animals that died and that were sacrificed on schedule were subject to gross pathological examination and the CHECKED (X) tissues were collected for histological examination. The (XX) organs in addition were weighed.

|    |                  |    |                    |    |                              |
|----|------------------|----|--------------------|----|------------------------------|
| X  | Digestive system | X  | Cardiovasc./Hemat. | X  | Neurologic                   |
|    | Tongue           | X  | Aorta*             | XX | Brain*                       |
| X  | Salivary glands* | XX | Heart*             | X  | Periph. nerve*               |
| X  | Esophagus*       | X  | Bone marrow*       | X  | Spinal cord                  |
| X  | Stomach*         | X  | Lymph nodes*       |    | (3 levels)*                  |
| X  | Duodenum*        | XX | Spleen*            | XX | Pituitary*                   |
| X  | Jejunum*         | X  | Thymus*            | X  | Eyes (optic n.)*             |
| X  | Ileum*           |    | Urogenital         |    | Glandular                    |
| X  | Cecum*           | XX | Kidneys*           | XX | Adrenals*                    |
| X  | Colon*           | X  | Urinary bladder*   | X  | Lacrimal gland               |
|    | Rectum*          | XX | Testes*            | X  | Mammary gland*               |
| XX | Liver*           | X  | Epididymides       | X  | Parathyroids*                |
| X  | Gallbladder*     | X  | Prostate           | XX | Thyroids*                    |
| X  | Pancreas*        | X  | Seminal vesicle    |    | Other                        |
|    | Respiratory      | XX | Ovaries            | X  | Bone* and bone marrow        |
| X  | Trachea*         | X  | Uterus*            | X  | Skeletal muscle*             |
| X  | Lung*            |    |                    | X  | Skin                         |
|    |                  |    |                    | X  | All gross lesions and masses |
|    |                  |    |                    | X  | Blood smear                  |
|    |                  |    |                    | X  | Head                         |
|    |                  |    |                    | X  | Harderian gland              |

\*Recommended by Subdivision F (October 1982) Guidelines for chronic studies.

00022

009614

Results

- a. Organ Weight - There were no statistically significant, dose-related intergroup differences in absolute and organ to body weight ratios and organ to brain weight ratios in male and female treated rats in comparison to controls. Therefore, there were no compound-related effects in organ weight.
- b. Gross Pathology - There were no compound-related effects in gross pathology. The postmortem findings occurred sporadically or were found in both control and treated rats and were not considered related to treatment.
- c. Microscopic Pathology

1. Nonneoplastic

Microscopic examination revealed lymphocytic hyperplasia of the thymus occurring at statistically significant incidences in the mid- and high-dose female rats.

A statistical analysis was previously conducted "Test for Significance of Differences Between Proportions" (February 5, 1982).

Lymphocytic Hyperplasia

| ppm     | No.<br>RESP | Total | %     | +/- | 2(SD)   | One Tail P Statistic<br>Fisher's |
|---------|-------------|-------|-------|-----|---------|----------------------------------|
| 0.000   | 5           | 25    | 20.00 | +/- | (17.63) |                                  |
| 30.000  | 13          | 32    | 40.63 | +/- | (18.58) | 0.084                            |
| 100.000 | 18          | 37    | 48.65 | +/- | (17.46) | 0.020                            |
| 300.000 | 17          | 34    | 50.00 | +/- | (18.28) | 0.017                            |

Test for a linear trend is not significant.

This lesion was not considered compound-related for the following reasons:

- a) This lesion is known to occur spontaneously in older rats and is quite variable in the thymus.
- b) There was no appreciable difference in the incidence of this lesion in the spleen, a much less variable indicator for lymphocytic hyperplasia.

00023

009614

- c) The severity was similar for control and treated rats, ranging from minimal to moderate.

A clear dose response was not evident and there were no changes in the hematology parameters in treated animals which would confirm the findings of the relationship of these lesions to treatment.

2) Neoplastic

Males - The interstitial cell tumor in the testis of male rats was observed in the following groups as shown below:

Group I (control) 0/50  
Group II (low dose) 3/50  
Group III (mid-dose) 1/50  
Group IV (high dose) 6/50

The occurrence of testicular interstitial tumors of 12 percent (6/50) in the high-dose group is statistically significant ( $p = 0.013$ ).

To further examine these results, the historical control data for interstitial cell tumor of the testes were compiled. These control data include only those lifetime feeding studies with Charles River Sprague-Dawley rats conducted by Bio/Dynamics, Inc. which were tested concurrently with the present study, i.e., were completed within 9 months of termination of the present study, and lasted at least 24 months. For all male animals on test, the high-dose group incidence in the present study is 12 percent (6/50) and was slightly higher than the highest concurrent control incidence of 7 percent (5/75) and higher than the overall incidence of 4.5 percent (24/535).

Additional historical control data were obtained from Charles River Breeding Laboratories (Patricia Lang, 1985) from 24-month studies conducted between 1977 and 1985 using Sprague-Dawley rats provided by Charles River Breeding Laboratories. The data consisted of 11 groups of control animals from various laboratories.

00024

009614

| <u>Location &amp; Tumor</u>   | <u>No.<br/>Exam</u> | <u>No.<br/>Tumor</u> | <u>Percent</u> | <u>Range</u> |
|-------------------------------|---------------------|----------------------|----------------|--------------|
| <u>Testis</u>                 | 880                 |                      |                |              |
| Interstitial cell tumor (B)   |                     | 31                   | 3.5            | 0 - 12.0     |
| Interstitial cell tumor (M)   |                     | 1                    | 0.1            | 0 - 1.1      |
| Interstitial cell tumor (NOS) |                     | 23                   | 2.6            | 0 - 9.1      |

Individual studies are shown below.

Expanded Table of Testicular Tumors in  
CD® Rats: 24 Months

| <u>Tumor</u>                  | <u>Group</u> |    |    |    |    |     |    |    |    |    |    |
|-------------------------------|--------------|----|----|----|----|-----|----|----|----|----|----|
|                               | A            | B  | C  | D  | E  | F   | G  | H  | I  | J  | K  |
| N =                           | 80           | 80 | 86 | 75 | 75 | 100 | 90 | 55 | 89 | 75 | 75 |
| Interstitial cell tumor (B)   | --           | -- | 2  | 2  | 2  | 6   | 4  | -- | -- | 9  | 6  |
| Interstitial cell tumor (M)   | --           | -- | -- | -- | -- | --  | 1  | -- | -- | -- | -- |
| Interstitial cell tumor (NOS) | 3            | 7  | -- | -- | -- | --  | -- | 5  | 8  | -- | -- |

It can be seen from the Charles River Data Base that the upper end of the range reaches 12.0 percent which was the incidence level in the high-dose glyphosate group.

In view of the totality of data, Toxicology Branch (TB) agrees with the study pathologist, Dr. Martin G. Robl of EPL who states in the report: "The significance, if any, of the 12% incidence of interstitial cell tumor in the testis in the high dose group of male rats in this study in comparison to control group is not known. It may represent a biological variation in this strain of rats. The incidence of interstitial cell tumor in the testis in Group II and Group III of this study was similar to the incidence observed in the control groups of male rats in the other concurrent studies and did not appear to be related to the administration of the test compound in this study."

TB concluded that glyphosate was not carcinogenic to interstitial cells (Leydig cells) of the testes of male rats.

Females - It was observed that there was an increased incidence of C-cell carcinomas in female rats at the high dose in comparison to controls.

00025



009614

Incidence (Percent) of Sprague-Dawley Females Bearing Thyroid  
C-Cell Tumors of All Animals Examined

| <u>Group</u>            | <u>Control</u> | <u>Low Dose</u> | <u>Mid Dose</u> | <u>High Dose</u> |
|-------------------------|----------------|-----------------|-----------------|------------------|
| <u>Tumor</u>            | 0              | 3 (mg/kg/day)   | 10              | 30               |
| Adenoma                 | 5/47 (11)      | 3/49 (6)        | 6/50 (12)       | 3/47 (6)         |
| Carcinoma               | 1/47 (2)       | 0/49 (0)        | 2/50 (4)        | 6/47 (13)        |
| Adenoma or<br>Carcinoma | 6/47 (13)      | 3/49 (6)        | 8/50 (16)       | 9/47 (19)        |

The above table shows that the percent incidence of carcinomas for all female animals examined is 2 percent in the controls and 13 percent in the high-dose animals. Additionally, the percent incidence of adenoma and carcinoma combined in Table II shows that the controls (13%) are comparable to the high-dose (19%).

The time-to-tumors data also shows that the latency of tumors is not affected by treatment. Thyroid weights showed no treatment-related increases and thyroid tumors were not grossly observed except for female rat #831 which had thyroid carcinoma.

Time-to-Tumor Data of Animals/Moribund Sacrifice  
and Died on Study/Sprague-Dawley Female Thyroid Tumors

Group I - Controls

| <u>Animal Number</u> | <u>Tumors</u> | <u>Days</u> | <u>Weeks</u> |
|----------------------|---------------|-------------|--------------|
| 225                  | Adenoma       | 702         | 100.3        |
| 229                  | Adenoma       | 629         | 89.9         |
| 234                  | Adenoma       | 699         | 100.0        |

Group II - Low-Dose

| <u>Animal Number</u> | <u>Tumors</u> | <u>Days</u> | <u>Weeks</u> |
|----------------------|---------------|-------------|--------------|
| 443                  | Adenoma       | 703         | 100.4        |

Group III - Mid-Dose

| <u>Animal Number</u> | <u>Tumors</u> | <u>Days</u> | <u>Weeks</u> |
|----------------------|---------------|-------------|--------------|
| 618                  | Adenoma       | 748         | 106.9        |
| 638                  | Adenoma       | 605         | 86.4         |
| 641                  | Carcinoma     | 677         | 96.7         |

009614

Group IV - High-Dose

| <u>Animal Number</u> | <u>Tumors</u> | <u>Days</u> | <u>Weeks</u> |
|----------------------|---------------|-------------|--------------|
| 803                  | Adenoma       | 689         | 98.4         |
| 820                  | Carcinoma     | 751         | 107.3        |
| 822                  | Adenoma       | 751         | 107.3        |
| 831                  | Carcinoma     | 778         | 111.1        |
| 834                  | Carcinoma     | 734         | 104.9        |
| 835                  | Carcinoma     | 652         | 93.1         |

The following table presents the Bio/Dynamics thyroid C-cell tumor historical control data on female Charles River albino (CD) rats.

Bio/Dynamics Thyroid C-Cell Tumor Historical Control Data:  
Female Charles River Albino (CD) (Sprague-Dawley Rats)

Incidence (Percent) of Females Bearing Thyroid C-Cell Tumors All Animals Sacrificed Post 12 Months

| <u>Study</u> | <u>Adenoma or Carcinoma</u> | <u>Adenoma</u> | <u>Carcinoma</u> |
|--------------|-----------------------------|----------------|------------------|
| <u>B</u>     |                             |                |                  |
| Group A*     | 10/58 (17)                  | 10/58 (17)     | 0/58 (0)         |
| Group B      | 7/59 (12)                   | 6/59 (10)      | 1/59 (2)         |
| <u>C</u>     |                             |                |                  |
| Group A      | 5/59 (8)                    | 5/59 (8)       | 0/59 (0)         |
| Group B      | 6/85 (10)                   | 6/58 (10)      | 0/58 (0)         |
| <u>I</u>     |                             |                |                  |
| Group A      | 9/57 (16)                   | 6/57 (11)      | 3/57 (5)         |
| Group B      | 6/55 (11)                   | 5/55 (9)       | 1/55 (2)         |
| <u>J</u>     |                             |                |                  |
| Group A      | 2/58 (3)                    | 2/58 (3)       | 0/58 (0)         |
| Group B      | 0/55 (0)                    | 0/55 (0)       | 0/55 (0)         |
| <u>L</u>     | 1/53 (2)                    | 1/53 (2)       | 0/53 (0)         |

\*Studies #B, C, I, and J had two control groups per study, identified as Group A or B.

The historical control data from Bio/Dynamics presented above shows that the percent incidence of carcinomas varied from 0 to 5 percent, whereas

009614

the percent incidence of adenomas or carcinomas varied from 0 to 17 percent.

With respect to the Charles River Breeding Laboratories Data Base (Patricia Lang, 1985) from 24-month studies conducted between 1977 and 1985 using Sprague-Dawley rats provided by Charles River Breeding Laboratories, the data consisted of 11 groups of control animals from various laboratories.

| <u>Location &amp; Tumor</u> | <u>No.<br/>Exam.</u> | <u>No.<br/>Tumor</u> | <u>Percent</u> | <u>Range</u> |
|-----------------------------|----------------------|----------------------|----------------|--------------|
| Thyroid gland               | 869                  |                      |                |              |
| C-cell adenoma              |                      | 36                   | 4.1            | 0 - 13.5     |
| Medullary carcinoma         |                      | 10                   | 1.2            | 0 - 4.0      |

It can be seen that the range of carcinomas is from 0 to 4.0 percent, similar to Bio/Dynamics.

Expanded Table of Thyroid Tumors in  
CD® Rats: 24 Months

| <u>Tumor</u>                | <u>Group</u> |    |    |    |    |    |    |    |    |    |    |
|-----------------------------|--------------|----|----|----|----|----|----|----|----|----|----|
|                             | A            | B  | C  | D  | E  | F  | G  | H  | I  | J  | K  |
| N =                         | 78           | 80 | 86 | 75 | 74 | 98 | 90 | 55 | 86 | 73 | 74 |
| Follicular cell adenoma     | 1            | -- | 1  | -- | -- | -- | -- | 1  | -- | -- | 1  |
| Follicular cell carcinoma   | --           | -- | -- | -- | -- | 2  | -- | 5  | 4  | -- | -- |
| C-cell adenoma              | 1            | 1  | 1  | 4  | 3  | 8  | -- | -- | -- | 8  | 10 |
| Medullary carcinoma         | --           | -- | 2  | 3  | 2  | 3  | -- | -- | -- | -- | -- |
| Carcinoma, undifferentiated | --           | -- | -- | -- | -- | -- | 5  | -- | -- | -- | -- |
| Adenoma, (NOS)              | 1            | -- | -- | -- | -- | -- | 2  | -- | -- | -- | -- |

Literature sources of C-cell thyroid tumors have been researched and provide the following information in Tables I through VI.

A spontaneous incidence of 22 percent C-cell tumors in Sprague-Dawley rats has been reported as shown in Table I (Table 12.2, Page 1056).

Tables I and II present the incidence of C-cell tumors in various strains of rats from published literature.

Table I: Tumors of Rat Strains Thyroid, Parafollicular Cell\*

| <u>Strain</u>  | <u>Average Incidence (%)</u> | <u>(Months)</u> | <u>Comments</u>   |
|----------------|------------------------------|-----------------|-------------------|
| Buffalo        | 25                           | > 24            | Increase with age |
| Fisher         | 22                           | > 24            | Increase with age |
| Long-Evans     | 12 - 45                      | > 24            | Increase with age |
| OM             | 33                           | > 24            | Increase with age |
| Sprague-Dawley | 22                           | > 24            | Increase with age |
| Wistar         | 19                           | > 24            | Increase with age |

\*Benvischke et al., Reference 1

Also, Tables I and II show the spontaneous incidence of C-cell tumors in other strains of rats.

Table II: Pathology of Aging Rats\*

Summary of the Incidence of Medullary Thyroid Carcinomas and Metastases of Medullary Thyroid Carcinomas in Aging BN/Bi, WAG/Rij, and (WAG x BN) F<sub>1</sub> Rats.\*

| <u>Strain</u>  | <u>Sex</u> | <u>No. Examined</u> | <u>No. with Medullary Thyroid Carcinoma</u> | <u>Percent</u> | <u>Mean Age (Range) In Months</u> | <u>No. Medullary Thyroid Carcinoma with Metastases</u> | <u>Age (in months) of Rats with Metastatic Medullary Thyroid Carcinomas</u> |
|----------------|------------|---------------------|---------------------------------------------|----------------|-----------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------|
| Bn/Bi          | Female     | 236                 | 15                                          | 6              | 33 (17-38)                        | 2                                                      | 35, 38                                                                      |
|                | Male       | 74                  | 7                                           | 9              | 27 (15-34)                        | 0                                                      |                                                                             |
| WAG/Rij        | Female     | 101                 | 47                                          | 47             | 35 (26-46)                        | 5                                                      | 35 (32-39)<br>29                                                            |
|                | Male       | 124                 | 41                                          | 33             | 23 (9-29)                         | 1                                                      |                                                                             |
| F <sub>1</sub> | Female     | 68                  | 11                                          | 16             | 31 (17-38)                        | 3                                                      | 25, 27, 28<br>28, 30, 38                                                    |
|                | Male       | 67                  | 20                                          | 29             | 34 (22-42)                        | 3                                                      |                                                                             |

\*Burek (1978), Reference 2

These references show a high spontaneous incidence of C-cell carcinomas in various strain of female rats.

009614

Other specific literature sources revealed the following information. Thompson and Hunt (1963) showed the following results:

Table III: Summary of Spontaneous Tumors Observed Upon Reexamination of Serial Sections of Selected Tissues from 177 (63 Males, 114 Females) Sprague-Dawley Pats

| Type of Tissue<br>and Tumor      | No. of<br>Organs<br>Examined | Number of Tumors  |        |                   |        | Age in Days |
|----------------------------------|------------------------------|-------------------|--------|-------------------|--------|-------------|
|                                  |                              | Single<br>Section |        | Serial<br>Section |        |             |
|                                  |                              | Male              | Female | Male              | Female |             |
| Thyroid<br>light cell<br>adenoma | 140                          | 4                 | 5      | 24                | 31     | 300-960     |

The following quote is taken from their 1963 publication and illustrates the increase in tumors found by serial sectioning. "As depicted in Table 1, (Table III, above) a total of 55 lightcell adenomas (24 males, 31 females) were encountered upon re-examination of serial tissue sections of 140 thyroid glands (54 males, 86 females). Only nine of these tumors (four males, five females) were originally observed in single random tissue sections of the thyroid glands of 177 rats (63 males, 114 females). All the nodules were of similar histologic structure, being composed of epithelial cells with leptochromatic nuclei, surrounded by a pale, slightly eosinophilic cytoplasm. Mitotic figures were not common, and the cells tended to be organized into lobules. Follicles were not formed by the tumor cells. However, small colloid filled follicles were frequently seen within the substance of these tumors, but were thought to represent normal thyroid follicles which had become encompassed as the tumors enlarged. These nodules varied in size from a microscopic collection of light-cells to large nodules which almost completely replaced the thyroid gland. The smaller nodules were always observed in the central portion of the gland; never occurring at the periphery or in the isthmus. The nodules were frequently encountered in both lobes of the thyroid. The age range of the rats in which light-cell adenomas were observed was 300 to 960 days with a mean of 637 days."

009614

Mackenzie and Garner (1973) presented the following information which shows the difficulty in assessing endocrine adenomas and carcinomas.

"A neoplasm was defined as a lesion with cellular architectural change; it expanded and compressed surrounding tissue noticeably. Size of tumor was not a criterion, if compressed tissue was demonstrable. Many tumors were microscopic and found on a single random section of each organ. No attempt was made to cut deeper into the blocks available, on the chance that additional small neoplasms might be uncovered. The criterion used to diagnose malignancy was the evidence of growth by invasion and/or metastasis. As the material submitted was often inadequate to demonstrate invasion, those tumors morphologically similar to known malignant tumors of the same type were also considered malignant. Neoplasms of the endocrine system, however, could not be classed accurately as benign or malignant by histology, and these are simply called adenomas."

MacKenzie and Garner (1973) examined six sources of rats and found the following results:

Table IV: Sources of Rats

| <u>Source and Identification</u>             | <u>Number of Rats</u> | <u>Remarks</u>                                                                                                |
|----------------------------------------------|-----------------------|---------------------------------------------------------------------------------------------------------------|
| Sprague-Dawley, Inc.<br>(Sprague-Dawley).    | 258                   | Colony originated in 1929. Closed colonies, random breeding.                                                  |
| Charles River, Inc.<br>(Charles River - SD). | 535                   | Original stock from Sprague-Dawley, Inc. Selectively random bred.                                             |
| Holtzman, Inc.<br>(Holtzman - SD).           | 208                   | Nucleus stock from Sprague-Dawley in 1946. Closed colony selectively random bred.                             |
| Diablo Animal Laboratories<br>(Diablo-SD).   | 217                   | Nucleus stock from Holtzman, Inc. (Sprague-Dawley strain). Maintained closed colony, selectively random bred. |

00031

009614

Table IV: - Sources of Rats (cont'd)

| <u>Source and Identification</u>  | <u>Number of Rats</u> | <u>Remarks</u>                                                                                                 |
|-----------------------------------|-----------------------|----------------------------------------------------------------------------------------------------------------|
| Locally bred<br>(Osborne-Mendel). | 131                   | Nucleus stock from Food and Drug Administration Washington, DC. Bred as closed colony for 2 years for project. |
| Locally bred<br>(Oregon)          | 673                   | Closed colony for over 30 years. Random breeding. Original stock of unknown origin.                            |

Table V: Tumors and Organs of Origin in 2082 Rats of 6 Sources\*

| <u>Tumors</u>             | <u>Sprague-Dawley</u> | <u>Holtzman-SD</u> | <u>Charles River-SD</u> | <u>Diablo-SD</u> | <u>Osborne-Mendel</u> | <u>Oregon</u> | <u>Total</u> |
|---------------------------|-----------------------|--------------------|-------------------------|------------------|-----------------------|---------------|--------------|
| Number of Rats            | 258                   | 268                | 535                     | 217              | 131                   | 673           | 2082         |
| Thyroid:                  |                       |                    |                         |                  |                       |               |              |
| Light-cell adenoma        | 15                    | 9                  | 12                      | 8                | 2                     | 3             | 49           |
| Follicular cell carcinoma |                       |                    | 2                       |                  |                       |               | 2            |

\*MacKenzie and Garner (1973), Reference 7

Suzuki et al. (1979) showed the following results:

Table VI: Incidence and Location of Spontaneous Endocrine Tumors in Sprague-Dawley Rats Surviving for More Than 2 Years

| <u>Sex</u> | <u>Effective No. of Animals</u> | <u>No. of Tumor-Bearing Animals</u> | <u>Thyroid Medullary Carcinoma</u> |
|------------|---------------------------------|-------------------------------------|------------------------------------|
| Male       | 42                              | 36 (86)                             | 33 (79)*                           |
| Female     | 39                              | 28 (72)                             | 19 (49)                            |

\*Numbers in parentheses indicate percentage (%).

Suzuki et al. (1979) show a high incidence of medullary thyroid carcinomas (49%) in female Sprague-Dawley rats.

00032

009614

D. References:

1. K. Benvischke, F.M. Garner, and T.C. Jones; PATHOLOGY OF LABORATORY ANIMALS (1978); Volume II; editors, Springer-Verlag pages 1231-1232.
2. J.D. Burek; PATHOLOGY OF AGING RATS (1978); CRC Press, Inc.; page 33.
3. A LIFETIME FEEDING STUDY OF GLYPHOSATE IN RATS; BDN-77-416; January 7, 1981.
4. AN ADDENDUM TO A LIFETIME FEEDING STUDY OF GLYPHOSATE IN RATS: Special Report MSL-2009; January 26, 1983.
5. H. Suzuki, U. Mohr, and G. Kimmerle, SPONTANEOUS ENDOCRINE TUMORS IN SPRAGUE-DAWLEY RATS; (1979); J. Cancer Res. Clin. Oncol. 95. 187-1961.
6. Thompson, S.W. and R.D. Hunt; SPONTANEOUS TUMORS IN THE SPRAGUE-DAWLEY RAT: Incidence rates some types of neoplasms as determined by serial section versus single section technics (1963) Ann. NY. Acad. Sci. 108:832-845.
7. MacKenzie, W.F. and F.M. Garner; COMPARISON OF NEOPLASMS IN SIX SOURCES OF RATS: (1973); J. Natl. Cancer Institute 50:1243-1257.

Consulting EPL pathologists, Dr. Martin G. Pobl and Dr. William E. Ribelin, addressed the issue of the increased incidence of C-cell carcinoma in high-dose female rats.

In a November 9, 1982 letter from Dr. Ribelin to Dr. Oleson of Monsanto, the following was stated:

"You recently asked me to send you a note regarding my interpretation of the significance of the incidence of thyroid C-cell (light cell) carcinomas in the high-dose level rats on the Bio/dynamics study of Roundup.

"The segregation of thyroid, and many other organs, proliferative lesions into hyperplasia, adenoma, and carcinoma will vary among pathologists. Indeed, when one considers the rat is merely a surrogate for man then the distinction between these three classes becomes even more nebulous. Carcinomas do not appear instantly but commence at stages when they are generally recognized only as hyperplasias, progress sometimes to adenomas, then occasionally proceed to adenocarcinomas. Thus, if one were dealing with a carcinogenic phenomena one would expect also an increase in C-cell hyperplasias and adenomas in the treated



009614

group. This is not the case here. The percentage of both hyperplasias and adenomas is greater in the control females than in the high dose level females.

"If one combines the proliferative C-cell lesions of these groups in this study the following results:

| <u>Group</u> | <u>1 (Control)</u> | <u>4</u> |
|--------------|--------------------|----------|
| Examined     | 47                 | 47       |
| Hyperplasia  | 19                 | 18       |
| Adenoma      | 5                  | 3        |
| Carcinoma    | 1                  | 6        |
| Total        | 25                 | 27       |
| Percent      | 53.2               | 57.4     |

"I find these differences insignificant and cannot ascribe any treatment effect from this data."

In a November 29, 1982 letter from Dr. Robl to Dr. Oleson of Monsanto, Dr. Robl states the following:

"This is in reply to your recent inquiry to EPL about 'A Lifetime Feeding Study of Glyphosate (Roundup® Technical) in Rats,' Bio/dynamics Project Number M-6, 77-2062 dated July 17, 1981, regarding c-cell changes in the thyroid. This letter also confirms our telephone conversation of November 18, 1982.

"I have reviewed the incidence of proliferative changes regarding thyroid c-cell changes in rats on this study. When evaluating proliferative changes in the endocrine system of rats for possible carcinogenic effects, the evaluation should include the comparison of the incidence of all the proliferative changes including hyperplasias, adenomas, and carcinomas. Granted, there is some difference in incidence of adenomas and carcinomas among some of the test groups in comparison to the control groups. However, the overall combined incidence of all the proliferative changes in the treated groups of animals is quite similar to the incidence in the control groups.

"If a carcinogenic effect was present, it would be expected that there would be a dose-related change in all aspects of proliferative changes. This was not evident when the incidence of all the proliferative changes of the c-cell was evaluated. The lung is often one of the most common sites for metastatic foci of c-cell tumors in the rat. Metastatic foci are a true

00961F

indication of malignancy in tumors. There were no metastatic foci present in the lungs of rats on this study.

"For reasons I have noted, it is my opinion that there does not appear to be a treatment-related effect upon the proliferative changes in the thyroid c-cell in this study."

Dr. Kasza recommended that the thyroid slides be reevaluated by Dr. Capen, an EPA consultant pathologist.

Relative to the Capen review, Dr. Kasza presented the following evaluation and conclusions; "Dr. Charles C. Capen, D.V.M., Ph.D.; Diplomate, American College of Veterinary Pathologists, has completed his investigation and basically he confirmed the diagnoses of the sponsor's pathologist; the tabulated results of Dr. Capen's investigation is shown below.

**"Histopathologic Evaluation of Thyroid Glands  
From Female Sprague-Dawley (C/D) Rats  
Lifetime Feeding of Glyphosate**

| <u>Thyroid Lesion*</u>                         | <u>Control<br/>(n = 47)</u> | <u>Low Dose<br/>(n = 49)</u> | <u>Medium Dose<br/>(n = 50)</u> | <u>High Dose<br/>(n = 47)</u> |
|------------------------------------------------|-----------------------------|------------------------------|---------------------------------|-------------------------------|
| C-Cell Hyperplasia<br>(Nodular and/or Diffuse) | 19<br>(40%)                 | 26<br>(53%)                  | 25<br>(50%)                     | 18<br>(38%)                   |
| C-Cell Adenoma                                 | 5<br>(11%)                  | 3<br>(6%)                    | 7**<br>(14%)                    | 3<br>(6%)                     |
| C-Cell Carcinoma                               | 1<br>(2%)                   | 0<br>(%)                     | 1<br>(2%)                       | 5***<br>(11%)                 |

(n =) Number of thyroids available for microscopic evaluation.

\*Diagnostic criteria used for thyroid C-cell lesions are given below.

\*\*One previously diagnosed C-cell carcinoma (81-1168/603) was interpreted to be a C-cell adenoma according to criteria below.

\*\*\*One previously diagnosed C-cell adenoma (81-1447/822) was interpreted to be multinodular chief cell hyperplasia of parathyroid gland; one C-cell carcinoma (81-1454/820) was interpreted to be a C-cell adenoma; one C-cell carcinoma (81-1454/824) was interpreted to be a C-cell adenoma; one C-cell adenoma (81-1231/828) was interpreted to be a C-cell carcinoma according to criteria below.

"The following are diagnostic criteria used for the interpretation of thyroid C-cell lesions in the rat:

"1. C-(parafollicular) cell hyperplasia: A nodular and/or diffuse increase of C-cells between thyroid follicles and/or within the follicular basement membrane. The C-cells appear normal with an abundant, lightly eosinophilic, granular cytoplasm and a round-to-oval nucleus with finely stippled chromatin. Cell boundaries often are indistinct. Solid accumulations of C-cells are less than the size of a colloid-distended follicle. C-cells (1-2 cell layers thick) within the basement membrane may compress individual thyroid follicles.

"2. C-(parafollicular) cell adenoma: Discrete, expansive mass or nodule of C-cells larger than a colloid-distended thyroid follicle. Adenomas are well-circumscribed or partially encapsulated from adjacent follicles that often are compressed to varying degrees. C-cells have an abundant cytoplasmic area that stains lightly eosinophilic and a round-to-oval nucleus with finely stippled chromatin. C-cells may be subdivided by fine connective tissue septae and capillaries into small clusters.

"3. C-(parafollicular) cell carcinoma: Extensive proliferation of C-cells with enlargement of one or both thyroid lobes. There is evidence of intrathyroid and/or capsular invasion by the proliferating C-cells, often with areas of hemorrhage and necrosis within the neoplasm. The malignant C-cells often are more pleomorphic (cuboidal, oval, spindle-shaped) than with the benign proliferative lesions and have indistinct boundaries of the lightly eosinophilic cytoplasmic area. Mitotic figures may be numerous in the more anaplastic carcinomas."

Dr. Kasza continued, "We concluded from his review that some tumor diagnoses were changed mainly from malignant to benign. This indicated that the interpretation of benign and malignant neoplasms in the thyroid of rats sometimes varies according to individual pathologists.

"Furthermore, a group of pathologists recently initiated a simplified method\* to establish oncogenicity related to chemicals. Although this system has not yet received general acceptance, many highly competent pathologists agree with it. This system advocates grouping of neoplasms to determine the incidence in final analysis. The grouping of neoplasms took place on the consideration of their histogenetic origin.

---

\*Working Paper entitled "Guidelines for Combining Benign and Malignant Neoplasms As An Aid In Determining Evidence of Carcinogenicity" (Attachment 8) discussed at the National Toxicology Program, (NTP) Board of Scientific Counselors' Meeting, September 23 and 24, 1982.

009614

According to this recommendation the C-cell adenomas and C-cell carcinomas in rats should be combined in order to establish oncogenicity. This recommendation was based on findings in Fisher 344 rats; however, we have no reason to believe that diagnostic criteria would be any different for the strain (Sprague-Dawley) used in the glyphosate study. We agree with the recommendation of NTP. In addition, we also consider that the differentiation between benign and malignant C-cell tumors can somewhat differ based on varying criteria of individual pathologists.

"Considering the above-mentioned two facts (Dr. Capen's diagnoses and the National Toxicology Program recommendation) we feel that we should combine thyroid benign and malignant C-cell tumors in order to evaluate the oncogenic potential of glyphosate in this rat lifetime study. When the combined incidence is compared there are no statistically significant differences between control (6/47) and test groups (3/49, 8/50, and 8/47)."

Based on all of the above information, Toxicology Branch concluded that C-cell thyroid carcinomas in high-dose female rats were not compound-related.

Attachment

00037

009614

R:62817:Dykstra:LHED-7:KEVRIC:04/22/91:PERM:EK/CL:WO:CL  
R:62824:Dykstra:LHED-7:KEVRIC:05/09/91:06/07/91:CL:WO:CL

00033

Page \_\_\_\_\_ is not included in this copy.

Pages 39 through 40 are not included.

The material not included contains the following type of information:

- \_\_\_\_ Identity of product inert ingredients.
- \_\_\_\_ Identity of product impurities.
- \_\_\_\_ Description of the product manufacturing process.
- \_\_\_\_ Description of quality control procedures.
- \_\_\_\_ Identity of the source of product ingredients.
- \_\_\_\_ Sales or other commercial/financial information.
- \_\_\_\_ A draft product label.
- \_\_\_\_ The product confidential statement of formula.
- \_\_\_\_ Information about a pending registration action.
- ☒ FIFRA registration data.
- \_\_\_\_ The document is a duplicate of page(s) \_\_\_\_\_.
- \_\_\_\_ The document is not responsive to the request.

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

009614

Reviewed by: William Dykstra, Ph.D.  
Section 1, Tox. Branch I, IRS, H7509C  
Secondary reviewer: Roger Gardner, Section Head  
Section I, Tox. Branch I, IRS, H7509C

*William Dykstra 5/14/91*

*Parrela M. Hurley 5/14/91*

DATA EVALUATION REPORT

STUDY TYPE: 83-3, teratology rat TOX. CHEM. NO.: 661A

ACCESSION NUMBER: N/A MRID No. 00046362

TEST MATERIAL: glyphosate, technical; 98.7 purity;  
Lot XHJ-64; white powder

SYNONYMS: Roundup

STUDY NUMBER (s): IRDL No. 401-054

SPONSOR: Monsanto Co., St. Louis, MO

TESTING FACILITY: IRDL, Mattawan, MI

TITLE OF REPORT: Teratology Study in Rats

AUTHOR(s): Dean E. Rodwell, Director of Teratology

REPORT ISSUED: March 21, 1980

Technical glyphosate was tested in a developmental toxicity study in rats at the following dose levels: 0, 300, 1000 or 3500 mg/kg bw/day.

CONCLUSIONS: The developmental NOEL is 1000 mg/kg/day, (mid-dose). The development LEL is 3500 mg/kg/day (high-dose). Although the findings at 3500 mg/kg/day include more malformed fetuses (10) than in the controls (3), the number of litters with malformed fetuses was the same (3) for both groups. Therefore, this was not considered an effect. The effects were an increase in the number of litters and fetuses with unossified sternebrae, and a decrease in fetal body weight at the LEL.

The maternal NOEL IS 1000 mg/kg/day. The maternal LEL was 3500 mg/kg/day and the effects were 28% decrease in body weight gain, toxic signs, and six deaths.

Classification: Core-guideline

Special Review Criteria (40 CFR 154.7) N/A

Testing Guideline Satisfied: 83-3 (rat)

00041

## Review

009614

1. A Teratology Study in Rats  
(IRDC No. 401-504; March 21, 1980)

Test material: glyphosate, technical; 98.7% purity;  
Lot XHJ-64; white powder; source: Monsanto Co.

A Quality Assurance Statement was signed by Barry W. Benson on 3/20/80. This study was conducted prior to the publication of the EPA GLP's.

Animals: Approximately 14 week old Charles River COBS SD CD rats (The Charles River Breeding Labs, Inc., Portage, Michigan) were used in this study. All rats were individually housed in a controlled environment and fed Purina Rodent Laboratory Chow #5001 and tap water ad libitum. One female Sprague-Dawley rat was mated to one male Sprague-Dawley rat. The day that mating was detected (copulatory plug on vaginal sperm) was designated day 0 of gestation.

Randomized groups of 25 mated Sprague-Dawley rats were dosed daily during days 6-19 of gestation at a constant volume of 10 ml/kg with 0 (control, vehicle: 0.5% aqueous methocel), 300, 1000 or 3500 mg/kg BW of test material. Individual doses were determined from individual body weights on gestation day 6. No rationale was given on the selection of dose levels. The dosages were prepared daily as a suspension with a magnetic stirring bar maintaining the suspension during dosing.

## Methods:

### 1. Observations

Dams were observed daily for toxic sign, deaths, moribundity. Deceased animals were necropsied.

## Results:

There were no compound-related maternal effects at 300 and 1000 mg/kg/day. At the high-dose of 3500 mg/kg/day, all of the dams (except three) were observed at least once to display diarrhea, soft stool, breathing rattles, inactivity, and red matter in the region of nose, mouth, forelimbs, or dorsal head. There were six deaths. One each on gestation day 10 and 17 and two each on gestation day 11 and 12. The cause of death could not be determined.

### 2. Body weight, caesarean section, maternal and fetal observations

Individual maternal body weights were recorded on gestation days 0, 6, 9, 12, 16 and 20.

On gestation day 20, all surviving females were sacrificed and the uterus was excised and weighed. The locations of viable, nonviable fetuses, early and late resorptions, and the total number of implantations and corpora lutea were counted. The abdominal and visceral cavities of dams were examined for gross

00042



lesions.

All fetuses were individually weighed and examined for external malformations. Each fetus was sexed. One half of the fetuses from each litter were placed in Bouin's fixative for subsequent visceral examination by the Wilson method. The other half of the fetuses were fixed in alcohol, macerated in potassium hydroxide and stained with Alizarin Red S by the Dawson method for skeletal examination.

## Results

1. Body weight. There were no compound-related effects in maternal body weight at 300 and 1000 mg/kg/day. At 3500 mg/kg/day, there was a 28.5% decrease in body weight gain during the 0-20 day test period, primarily due to a body weight loss during gestation days 6-9. These results are shown below.

Summary of Group Mean Maternal Body Weights and Body Weight Change

| Day of Gestation                               | Control (o mg/kg/day) | 300  | Technical Glyphosate 1000 | mg/kg/day | 3500 |      |      |      |
|------------------------------------------------|-----------------------|------|---------------------------|-----------|------|------|------|------|
| Group Mean Maternal Body Weights               |                       |      |                           |           |      |      |      |      |
|                                                | Mean                  | S.D. | Mean                      | S.D.      | Mean | S.D. | Mean | S.D. |
| 0                                              | 270                   | 14.4 | 270                       | 22.8      | 274  | 15.9 | 261  | 16.8 |
| 6                                              | 297                   | 16.9 | 295                       | 22.9      | 302  | 18.5 | 288  | 15.8 |
| 9                                              | 305                   | 17.7 | 303                       | 23.7      | 307  | 16.5 | 275  | 29.4 |
| 12                                             | 318                   | 19.3 | 316                       | 26.2      | 322  | 17.7 | 299  | 31.4 |
| 16                                             | 350                   | 19.1 | 346                       | 32.6      | 352  | 21.3 | 326  | 35.3 |
| 20                                             | 416                   | 23.1 | 403                       | 47.0      | 416  | 22.1 | 373  | 43.1 |
| Group Mean Maternal Body Weight Change (grams) |                       |      |                           |           |      |      |      |      |
| 0 to 6                                         | 27                    | -    | 25                        | -         | 28   | -    | 27   | -    |
| 6 to 9                                         | 8                     | -    | 8                         | -         | 5    | -    | -13  | -    |
| 9 to 12                                        | 13                    | -    | 13                        | -         | 15   | -    | 24   | -    |
| 12 to 16                                       | 32                    | -    | 30                        | -         | 30   | -    | 27   | -    |
| 16 to 20                                       | 66                    | -    | 57                        | -         | 64   | -    | 47   | -    |
| 0 to 20                                        | 146                   | -    | 133                       | -         | 142  | -    | 112  | -    |
| S.D. - Standard Deviation<br>- Not applicable  |                       |      |                           |           |      |      |      |      |

## 2. Caesarean Section Results

At 300 and 1000 mg/kg/day, there were no toxicologically significant effects in mean number of viable fetuses, late or early resorptions, postimplantation loss, corpora lutea, the fetal sex distribution or fetal body weight. The decreases observed at 300 mg/kg/day in viable fetuses/dam and total implantations per dam were not considered compound-related since they were not dose-related. At 3500 mg/kg/day, the following

009614

effects were noted: Statistically significant decreases in viable fetuses/dam and total implantations/dam and mean fetal body weight. These findings are shown below:

| Summary of Group Mean Maternal and Fetal Observations at Cesarean Section |      |       |            |        |       |            |      |       |            |       |      |            |
|---------------------------------------------------------------------------|------|-------|------------|--------|-------|------------|------|-------|------------|-------|------|------------|
| Technical Glyphosate (mg/kg/day)                                          |      |       |            |        |       |            |      |       |            |       |      |            |
| 0                                                                         |      |       | 300        |        |       | 1000       |      |       | 3500       |       |      |            |
|                                                                           | No.  | %     | S.D.       | No.    | %     | S.D.       | No.  | %     | S.D.       | No.   | %    | S.D.       |
| Animal on Study:                                                          | 25   | -     | -          | 25     | -     | -          | 25   | -     | -          | 25    | -    | -          |
| Animals that were gravid:                                                 | 22   | 88.0  | -          | 20     | 80.0  | -          | 21   | 84.0  | -          | 23    | 92.0 | -          |
| Animals that died:                                                        | 0    | 0.0   | -          | 0      | 0.0   | -          | 0    | 0.0   | -          | 5     | 24.0 | -          |
| Nongravid:                                                                | 0    | 0.0   | -          | 0      | 0.0   | -          | 0    | 0.0   | -          | 3     | 9.0  | -          |
| Gravid:                                                                   | 0    | 0.0   | -          | 0      | 0.0   | -          | 0    | 0.0   | -          | 5     | 20.0 | -          |
| Animals examined at Cesarean Section:                                     | 25   | 100.0 | -          | 25     | 100.0 | -          | 25   | 100.0 | -          | 19    | 76.0 | -          |
| Nongravid:                                                                | 3    | 12.0  | -          | 5      | 20.0  | -          | 4    | 16.0  | -          | 2     | 10.5 | -          |
| Gravid:                                                                   | 22   | 88.0  | -          | 20     | 80.0  | -          | 21   | 84.0  | -          | 17    | 89.5 | -          |
| Dams with resorptions only:                                               | 0    | 0.0   | -          | 0      | 0.0   | -          | 0    | 0.0   | -          | 1     | 5.9  | -          |
| Dams with Viable fetuses:                                                 | 22   | 100.0 | -          | 20     | 100.0 | -          | 21   | 100.0 | -          | 16    | 94.1 | -          |
| Viable Fetuses/Dam:                                                       | 14.4 | -     | $\pm 1.26$ | 11.9*  | -     | $\pm 4.36$ | 14.3 | -     | $\pm 2.08$ | 11.5* | -    | $\pm 4.12$ |
| Post Implantation loss/dam:                                               | 0.6  | -     | $\pm 0.90$ | 0.2    | -     | $\pm 0.52$ | 0.5  | -     | $\pm 0.81$ | 1.2   | -    | $\pm 1.25$ |
| Total Implantation /Dam:                                                  | 15.0 | -     | $\pm 1.11$ | 12.1** | -     | $\pm 4.45$ | 14.8 | -     | $\pm 2.21$ | 12.8* | -    | $\pm 3.77$ |
| Corpora Lutea/Dam:                                                        | 15.9 | -     | $\pm 1.67$ | 15.2   | -     | $\pm 3.30$ | 16.1 | -     | $\pm 1.81$ | 14.8  | -    | $\pm 1.64$ |
| Fetal sex distribution                                                    |      |       |            |        |       |            |      |       |            |       |      |            |
| - Male:                                                                   | 159  | 50.3  | -          | 119    | 50.2  | -          | 168  | 56.0  | -          | 97    | 49.5 | -          |
| - Female:                                                                 | 159  | 49.0  | -          | 118    | 49.8  | -          | 132  | 44.0  | -          | 99    | 50.5 | -          |
| Mean fetal body weight (grams):                                           | 3.0  | -     | $\pm 0.21$ | 3.7    | -     | $\pm 0.66$ | 3.6  | -     | $\pm 0.19$ | 3.2** | -    | $\pm 0.34$ |
| *Significantly different from control group, mean $p < 0.05$ .            |      |       |            |        |       |            |      |       |            |       |      |            |
| **Significantly different from control group, mean $p < 0.01$ .           |      |       |            |        |       |            |      |       |            |       |      |            |
| S.D. - Standard Deviation                                                 |      |       |            |        |       |            |      |       |            |       |      |            |
| - Not applicable                                                          |      |       |            |        |       |            |      |       |            |       |      |            |

00044

### 3. Fetal Morphological observations

There were no malformations in the 300 and 1000 mg/kg/day groups. Three control litters (dam #19999, 20002 and 20016) and three litters from the high-dose (dams # 20083, 20091 and 20096) had malformed fetuses. Additionally, an increase in the number of litters and fetuses with unossified sternebrae was observed at 3500 mg/kg/day. Although the same number of litters with the malformed fetuses occurred in the control and high-dose group, several fetuses with either the anomaly classified as dwarfism or bent tails were found in single litters. As a result, there were more malformed fetuses in the high-dose group (10 fetuses) than in the controls (3 fetuses). Bent tail and dwarfism have occurred in several fetuses in a single litter from RDC historical controls. These results are shown below.

| Summary of the Incidence of Fetal Malformations and Developmental and Genetic Variations |      |                          |     |                         |  |
|------------------------------------------------------------------------------------------|------|--------------------------|-----|-------------------------|--|
| <u>Glyphosate (mg/kg/day)</u>                                                            |      | Control<br>(0 mg/kg/day) |     | <u>Technical</u><br>300 |  |
| 1000                                                                                     | 3500 |                          |     |                         |  |
| No. of litters examined:                                                                 | 32   | 10                       | 21  | 16                      |  |
| No. of fetuses examined externally:                                                      | 316  | 237                      | 300 | 196                     |  |
| No. of fetuses examined vicerally:                                                       | 155  | 119                      | 150 | 97                      |  |
| No. of fetuses examined skeletally:                                                      | 161  | 118                      | 150 | 99                      |  |

009614

| Malformations<br>Observed                        | Fetuses |            | Litters |             | Fetuses |            | Litters |           | Fetuses |            | Litters |           | Fetuses |            | Litters |             |
|--------------------------------------------------|---------|------------|---------|-------------|---------|------------|---------|-----------|---------|------------|---------|-----------|---------|------------|---------|-------------|
|                                                  | No.     | %          | No.     | %           | No.     | %          | No.     | %         | No.     | %          | No.     | %         | No.     | %          | No.     | %           |
| 1 mm vesicle<br>over posterior<br>fontanelle:    |         |            |         |             |         |            |         |           |         |            |         |           | 1       | 0.5        | 1       | 6.3         |
| Brain Anomaly:                                   | 1       | 0.3        | 1       | 4.5         |         |            |         |           |         |            |         |           |         |            |         |             |
| Dwarfism <sup>3</sup>                            |         |            |         |             |         |            |         |           |         |            |         |           | 3       | 1.5        | 1       | 6.3         |
| Rib forked:                                      | 1       | 0.3        | 1       | 4.5         |         |            |         |           |         |            |         |           |         |            |         |             |
| Tail threadlike<br>on anus:                      | 1       | 0.3        | 1       | 4.5         |         |            |         |           |         |            |         |           |         |            |         |             |
| Tail bent                                        |         |            |         |             |         |            |         |           |         |            |         |           | 5       | 8.1        | 1       | 6.3         |
| <b>TOTAL<br/>MALFORMATION</b>                    |         | <b>No.</b> |         | <b>%</b>    |         | <b>No.</b> |         | <b>%</b>  |         | <b>No.</b> |         | <b>%</b>  |         | <b>No.</b> |         | <b>%</b>    |
| Fetuses with soft<br>tissue<br>malformation      |         | 2          |         | 0.5         |         | 0          |         | 0.        |         | 0          |         | 0.        |         | 1          |         | 3.5         |
| Fetuses with<br>skeletal<br>malformations:       |         | 1          |         | 0.3         |         | 0          |         | 0.0       |         | 0          |         | 0.0       |         | 9          |         | 4.5         |
| <b>TOTAL fetuses<br/>with<br/>malformations:</b> |         | <b>3</b>   |         | <b>0.9</b>  |         | <b>0</b>   |         | <b>0.</b> |         | <b>0</b>   |         | <b>0.</b> |         | <b>10</b>  |         | <b>5.1</b>  |
| Litters with soft<br>tissue<br>malformations:    |         | 2          |         | 9.1         |         | 0          |         | 0.        |         | 0          |         | 0.        |         | 2          |         | 12.3        |
| Litters with<br>skeletal<br>malformations:       |         | 1          |         | 4.5         |         | 0          |         | 0.        |         | 0          |         | 0.        |         | 2          |         | 12.3        |
| <b>Total Litters<br/>with<br/>malformations:</b> |         | <b>3</b>   |         | <b>13.6</b> |         | <b>0</b>   |         | <b>0.</b> |         | <b>0</b>   |         | <b>0.</b> |         | <b>3</b>   |         | <b>18.9</b> |

00046

009614

| Developmental and Genetic Variations Observed       | Fetuses   Litters |      |    |      | Fetuses   Litters |      |    |      | Fetuses   Litters |      |    |      | Fetuses   Litters |      |    |      |
|-----------------------------------------------------|-------------------|------|----|------|-------------------|------|----|------|-------------------|------|----|------|-------------------|------|----|------|
|                                                     | No                | %    | No | %    | No.               | %    | No | %    | No                | %    | No |      | No                | %    | No | %    |
| 27 presacral vertebrae                              |                   |      |    |      | 1                 | 0.8  | 1  | 5.3  |                   |      |    |      |                   |      |    |      |
| 14th rudimentary rib(s)                             | 1                 | 11.1 | 9  | 40.9 | 19                | 16.1 | 8  | 40.6 | 25                | 16.7 | 14 | 50.7 | 13                | 13.1 | 8  | 50.0 |
| 7th cervical rib:                                   | 1                 | 0.6  | 1  | 4.5  | 1                 | 0.8  | 1  | 5.3  |                   |      |    |      |                   |      |    |      |
| Hyoid unossified:                                   | 2                 | 1.2  | 2  | 9.1  |                   |      |    |      | 6                 | 1.7  | 3  | 14.3 |                   |      |    |      |
| Reduced Ossification of Skull:                      | 1                 | 0.6  | 1  | 4.5  | 2                 | 1.7  | 2  | 10.5 | 1                 | 0.7  | 1  | 4.8  |                   |      |    |      |
| Sternebrae #5 and/or #6 unossified:                 | 13                | 8.1  | 8  | 34.4 | 7                 | 5.9  | 5  | 6.3  | 17                | 11.3 | 8  | 38.1 | 18                | 18.1 | 21 | 68.8 |
| Other Sternebrae unossified:                        | 1                 | 0.6  | 1  | 4.5  |                   |      |    |      |                   |      |    |      | 5                 | 6.1  | 3  | 18.2 |
| Retroesophageal right subclavian:                   |                   |      |    |      |                   |      |    |      |                   |      |    |      | 1                 | 1.3  | 2  | 6.3  |
| Renal papilla not developed and/or distended ureter | 3                 | 1.9  | 3  | 13.5 | 1                 | 0.8  | 1  | 5.0  | 4                 | 2.7  | 3  | 14.3 | 4                 | 4.1  | 4  | 15.3 |
| * P<0.05                                            |                   |      |    |      |                   |      |    |      |                   |      |    |      |                   |      |    |      |

The following table gives historical control data for this particular strain of rat in the same testing laboratory.

009614

| IRDC HISTORICAL CONTROL DATA/<br>Charles River CDMS CD Rats                              |                          |
|------------------------------------------------------------------------------------------|--------------------------|
| Summary of the Incidence of Malformations and<br>of Developmental and Genetic Variations |                          |
| No. of litters examined                                                                  | 524                      |
| Total no. of fetuses examined externally:                                                | 6955 <sup>b</sup>        |
| Total no. of fetuses examined skeletally:                                                | 4351                     |
| Total no. of fetuses examined visceraally:                                               | 2602                     |
| Malformations Observed                                                                   | No. of Fetuses (Litters) |
| Thread-like tail, small anus                                                             | 1 (1)                    |
| Rib anomalies:                                                                           | 14 (3)                   |
| Anophthalmia or microphthalmia:                                                          | 4 (4)                    |
| Scoliosis:                                                                               | 1 (1)                    |
| Malformed mandible:                                                                      | 1 (1)                    |
| Bent tail:                                                                               | 5 (1)                    |
| Multiple anomalies:                                                                      | 2 (2)                    |
| Fatal anasarca:                                                                          | 1 (1)                    |
| Diaphragmatic hernia:                                                                    | 1 (1)                    |
| Fused sternebrae:                                                                        | 1 (1)                    |
| Great vessel anomalies:                                                                  | 1 (1)                    |
| Dwarfism:                                                                                | 5 (1)                    |
| Tympanic ring malformed or absent:                                                       | 3 (1)                    |
| Total no. of fetuses (litters) with malformations:                                       | 38 (27)                  |
| Variations - Developmental and Genetic Observed                                          |                          |
| 27 presacral vertebrae:                                                                  | 31 (27)                  |
| 25 presacral vertebrae:                                                                  | 2 (2)                    |
| 12 full pair of ribs with 13th rudimentary rib(s) or<br>13th unilateral full rib:        | 7 (7)                    |
| 14th rudimentary rib(s):                                                                 | 796 (306)                |
| 14th full rib(s)                                                                         | 13 (12)                  |
| 7th cervical rib(s)                                                                      | 8 (7)                    |
| Extra ossification distal to 14th rib:                                                   | 1 (1)                    |
| Scapula variation:                                                                       | 1 (1)                    |
| Sternebrae misaligned:                                                                   | 3 (3)                    |
| Sternebrae #5 and/or #6 unossified                                                       | 550 (249)                |
| Other sternebrae unossified                                                              | 31 (26)                  |
| Entire sternum unossified                                                                | 2 (2)                    |
| Skull reduced in ossification:                                                           | 58 (37)                  |

(Variations - Developmental and Genetic Observed) cont'd pg 9)

| Variations - Developmental and Genetic Observed (cont'd)                                                                                    | No. of Fetuses (Litters) |
|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| Hyoid unossified:                                                                                                                           | 48 (31)                  |
| Vertebrae reduced in ossification:                                                                                                          | 5 (5)                    |
| Metacarpals or metatarsals unossified:                                                                                                      | 1 (1)                    |
| Entire skeleton reduced in ossification:                                                                                                    | 1 (1)                    |
| Renal papillae not developed and/or distended ureter:                                                                                       | 53 (46)                  |
| Pubis unossified:                                                                                                                           | 2 (2)                    |
| <sup>b</sup> Includes two fetuses that were sent to histology and were not included in the number of fetus examined skeletally or viscally. |                          |

### STATISTICAL ANALYSIS

All statistical analyses compared the treatment groups to the control group, with the level of significance at  $p < 0.05$ .

The male to female fetal sex distribution and the number of litters with malformations were compared using the Chi-square test criterion with Yates' correction for 2 x 2 contingency tables and/or Fisher's exact probability test as described by Siegel to judge significance of differences.

The mean number of viable fetuses, total implantations, corpora lutea and mean fetal body weights were compared by analysis of variance (one-way classification), Bartlett's test for homogeneity of variances and the appropriate t-test (for equal or unequal variances) as described by Steel and Torrie using Dunnett's multiple comparison tables to judge significance of differences.

### DISCUSSION:

1. Maternal Toxicity: decrease in body weight gain, toxic signs and death.
2. Developmental Toxicity: decreases in fetal body weight, increase in the number of litters and fetuses with unossified sternebrae, decreases in viable fetuses/dam and decreases in total implantations/dam.

Study Deficiencies: No major deficiencies.

### Core Classification: Core Guideline Data

Maternal NOEL = 1000 mg/kg/day

Maternal LOEL = 3500 mg/kg/day

Developmental Toxicity NOEL = 1000 mg/kg/day

Developmental Toxicity LOEL = 3500 mg/kg/day.

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/20/91*  
Section I, Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Pamela M. Hurley 5/20/91*  
Section I, Toxicology Branch I - IRS (H7509C)

009614

DATA EVALUATION REPORT

Study Type: 83-3 - Teratology - Rabbit TOX Chem. No.: 661A

Accession No.: N/A

MRID No.: 00046363

Test Material: Glyphosate, Technical; 98.7% Purity; White Powder; Lot XHJ-64

Synonyms: Roundup

Study No.: IRDC No. 401-056

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: IRDC, Mattawan, MI

Title of Report: Teratology Study in Rabbits.

Author: Dean E. Rodwell, M.S., Director of Teratology

Report Issued: February 29, 1980

Conclusions:

Glyphosate was tested in a developmental toxicity study in rabbits in which the animals received by gavage dosages of 0, 75, 175, and 350 mg/kg/day during days 6 to 27 of gestation.

The developmental toxicity NOEL was 350 mg/kg/day (HDT). The maternal toxicity NOEL was 175 mg/kg/day (mid-dose). The LEL was 350 mg/kg/day (HDT) and the effects were increased incidences of soft stool, diarrhea, nasal discharge, and death (10 does died on day 21).

Classification: Core-Minimum

Special Review Criteria (40 CFR 154.7): N/A

Testing Guideline Satisfied: 83-3 (Rabbit)

00030



009614

Review:

A Teratology Study in Rabbits (IRDC No. 401-056; February 29, 1980).

Test Material - Glyphosate, Technical; 98.7% purity; Lot No. XHJ-64; White Powder; Source: Monsanto Company.

A Quality Assurance Statement was signed by Barry W. Benson on February 21, 1980.

Animals - Virgin female Dutch Belted rabbits were purchased from Longshaw Farms, Augusta, Michigan at age 7 months. The animals were individually caged in controlled environment and received Purina Rabbit Chow Checkers 5301 and tap water ad libitum.

The female rabbits were artificially inseminated from semen from four proven male rabbit donors. Semen from one male was used to inseminate an equal number of females in each group. The day of insemination was designated as day 0 of gestation. The semen had been collected using an artificial vagina, evaluated for motility, and diluted with 0.9% sodium chloride solution prior to introduction into the anterior vagina of the female using an insemination pipette. Immediately after insemination, ovulation was induced by an injection of 100 units of chorionic gonadotropin into each female.

Methods:

Randomized groups of 16 rabbits were inseminated. Following insemination, single oral daily doses of test material were administered by gavage during days 6 to 27 of gestation at dosages of 0 (control: 0.5% aqueous methocel), 75, 175, and 350 mg/kg/day. A constant volume of 1 mL/kg was administered. No rationale for dose selection was given. The test article was suspended in vehicle daily. A magnetic stir bar and plate were used during administration to keep the material in suspension.

The does were observed daily for toxicity and mortality. Maternal body weights were determined on gestation days 0, 6, 12, 18, 24, and 28. Food consumption was not measured.

On gestation day 28, all surviving females were sacrificed. Does not surviving to the scheduled sacrifice were necropsied in an attempt to determine the cause of death. The uterus was examined, weighed, and the fetuses were removed. The number and location of viable fetuses, early and late resorptions, and the total number of implantations and corpora lutea were counted. The abdominal and thoracic cavities and viscera of the does were examined for gross lesions.

All fetuses were individually weighed and examined for external malformations. Each fetus was dissected, internally sexed, and examined for visceral malformations, including the brain by a mid-coronal slice. The heart was dissected by Staples method. The eviscerated, skinned fetuses were fixed in alcohol, macerated in KOH, and stained with Alizarin Red S by the Dawson method for skeletal examination.

#### Statistical Analysis:

All statistical analyses compared the treatment groups to the control group, with a level of significance at  $p < 0.05$ .

The male to female fetal sex distribution and the number of litters with malformations were compared using the Chi-square test criterion with Yates' correction for 2 x 2 contingency tables and/or Fisher's exact probability test as described by Siegel to judge significance of differences.

The number of early and late resorptions and postimplantation loss were compared by the Mann-Whitney U-test as described by Siegal and Weil to judge significance of differences.

The mean number of viable fetuses, total implantations, corpora lutea and mean fetal body weights were compared by analysis of variance (one-way classification), Bartlett's test for homogeneity of variances and the appropriate t-test (for equal or unequal variances) as described by Steel and Torrie using Dunnett's multiple comparison tables to judge significance of differences.

#### Quality Assurance:

A signed quality assurance statement was provided. This study was conducted prior to the publication of the EPA GLP's. No GLP statement was provided.

#### Results:

1. Maternal Toxicity and Mortality - Soft stool or diarrhea was noted in all groups with a slight increase at 175 mg/kg/day and at least once in each rabbit of the 350 mg/kg/day group. A definite increase in nasal discharge was also noted in the 350 mg/kg/day group.

As stated in the report:

"Two rabbits in the control group aborted and were sacrificed, both on gestation day 22. One rabbit in the 75 mg/kg/day dosage group died on gestation day 26. In the 175 mg/kg/day dosage group, one rabbit aborted and was sacrificed on gestation day 27 and two rabbits died, one each on gestation days 22 and 25. One rabbit in the

009614

350 mg/kg/day dosage group aborted and was sacrificed on gestation day 23 and 10 died by gestation day 21. One rabbit in this group died on gestation day 3. On the same day, a replacement female was selected and artificially inseminated.

"A cause of death was determined at necropsy for five rabbits only as indicated below:

| <u>Dam No.</u> | <u>Dosage Level<br/>(mg/kg/day)</u> | <u>Death attributed to:</u>              |
|----------------|-------------------------------------|------------------------------------------|
| 2243           | 75                                  | pneumonia                                |
| 2267           | 175                                 | gastroenteritis                          |
| 2286           | 350                                 | enteritis                                |
| 2278           | 350                                 | respiratory disease                      |
| 2380           | 350                                 | gasroenteritis and<br>caecal ulcerations |

"Causes of death for the other eight rabbits could not be determined at necropsy."

2. Maternal Body Weight - There were no toxicologically significant differences in mean body weight among control and treated groups as shown below:

Summary of Group Mean Maternal Body Weights and Body Weight Change

| Day of Gestation | Control<br>(0 mg/kg/day) |        | Technical Glyphosate (mg/kg/day) |        |      |        |      |        |
|------------------|--------------------------|--------|----------------------------------|--------|------|--------|------|--------|
|                  | Mean                     | S.D.   | 75                               |        | 175  |        | 350  |        |
|                  | Mean                     | S.D.   | Mean                             | S.D.   | Mean | S.D.   | Mean | S.D.   |
| 0                | 2958                     | +146.6 | 2876                             | +176.3 | 2983 | +157.5 | 2834 | +196.9 |
| 6                | 2988                     | +177.5 | 2937                             | +187.0 | 3012 | +206.9 | 2875 | +232.1 |
| 12               | 3039                     | +165.6 | 2986                             | +191.5 | 3029 | +216.1 | 2732 | +330.5 |
| 18               | 3072                     | +166.4 | 3002                             | +213.4 | 2959 | +276.6 | 2827 | +317.2 |
| 24               | 3038                     | +182.3 | 3005                             | +219.9 | 2914 | +321.2 | 2999 | +315.1 |
| 28               | 3030                     | +231.7 | 3008                             | +142.7 | 2958 | +307.5 | 2948 | +238.7 |

| Days of Gestation | Group Mean Maternal Body Weight Change (grams) |   |     |   |     |   |      |   |
|-------------------|------------------------------------------------|---|-----|---|-----|---|------|---|
| 0 to 6            | 30                                             | - | 61  | - | 29  | - | 41   | - |
| 6 to 12           | 51                                             | - | 49  | - | 17  | - | -143 | - |
| 12 to 18          | 33                                             | - | 16  | - | -70 | - | 95   | - |
| 18 to 24          | -34                                            | - | 3   | - | -45 | - | 172  | - |
| 24 to 28          | - 8                                            | - | 3   | - | 44  | - | -51  | - |
| 0 to 28           | 72                                             | - | 132 | - | -25 | - | 114  | - |

00053



type, and the frequency did not exceed the historical controls. The data are shown below:

Summary of the results of these field-studies and suggestions for the future.

[illegible]

**BEST AVAILABLE COPY**

00055

009614

Additionally, the incidences of percent litter and fetal variations were comparable between control and treated groups.

The following table gives historical control data from the same laboratory (dates not given).

INTERNATIONAL RESEARCH AND DEVELOPMENT CORPORATION  
HISTORICAL CONTROL DUTCH BELTED RABBITS

| Summary of the Incidence of Malformations and<br>of Developmental and Genetic Variations |                                               |
|------------------------------------------------------------------------------------------|-----------------------------------------------|
| Number of litter examined:                                                               | 23                                            |
| Total number of fetuses examined externally:                                             | 161                                           |
| Total number of fetuses examined skeletally:                                             | 161                                           |
| Total number of fetuses examined for soft tissue:                                        | 161                                           |
|                                                                                          | <u>Number of Fetuses<br/>(No. of Litters)</u> |
| <u>Malformations Observed</u>                                                            |                                               |
| Scoliosis with or without associated rib anomalies:                                      | 1 (1)                                         |
| Vertebral anomalies other than scoliosis:                                                | 1 (1)                                         |
| Additional ossification of the sternum:                                                  | 1 (1)                                         |
| Carpal and/or tarsal flexures:                                                           | 1 (1)                                         |
| Kidney and/or ureter anomalies:                                                          | 1 (1)                                         |
| Hydrocephaly:                                                                            | 1 (1)                                         |
| Heart anomalies:                                                                         | 1 (1)                                         |
| Spleen and pancreas absent, stomach on right side:                                       | 1 (1)                                         |
| Total number of fetuses (no. of litters) with malformations:                             | 6 (6)                                         |
| <u>Variations-Developmental and Genetic Observed</u>                                     |                                               |
| 27 presacral vertebrae:                                                                  | 14 (7)                                        |
| 13th rudimentary rib(s):                                                                 | 6 (6)                                         |
| 13th full rib(s):                                                                        | 13 (5)                                        |
| Sternebrae #5 and/or #6 unossified:                                                      | 9 (7)                                         |
| Sternebrae misaligned with or without fusion:                                            | 2 (2)                                         |
| Reduced ossification of the skull:                                                       | 1 (1)                                         |
| Accessory skull bone(s):                                                                 | 1 (1)                                         |
| Misshapen, misaligned vertebral centra:                                                  | 2 (2)                                         |
| Major vessel variations:                                                                 | 14 (7)                                        |
| Gallbladder variations:                                                                  | 2 (2)                                         |

00036

009614

Discussion:

1. Maternal Toxicity: Maternal toxicity was evident at the highest dose level. The effects included soft stool or diarrhea, nasal discharge, and death.
2. Developmental Toxicity: There were no toxicologically significant signs of developmental toxicity at any dose level.

Study Deficiencies

The major deficiency in this study is that 10 does died in the high-dose group. Thus, only six survived to full term and only six litters were examined. This decreases the confidence in the results.

Core Classification: Core Minimum Data

Maternal NOEL = 175 mg/kg/day

Maternal LOEL = 350 mg/kg/day

Developmental Toxicity NOEL = 350 mg/kg/day (HDT)

00057

009614

R:62820:Dykstra:LHED-05:KEVRIC:04/23/91:05/19/91:aw:WO:CL  
R:62828:Dykstra:LHED-05:KEVRIC:05/17/91:06/13/91:aw:wo:aw

00058



009614

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/14/91*  
Section I, Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Anne M. Hurley 5/14/91*  
Section I, Toxicology Branch I - IRS (H7509C)

DATA EVALUATION REPORT

Study Type: 33-4, Two-Generation  
Reproduction - Rat

TOX Chem. No.: 661A

Accession No.: 245909

MRID No.: 00105995

Test Material: Glyphosate; technical; 98.7% purity; Lot No.  
XHJ-64

Synonyms: Roundup

Study Number: Bio/dynamics Project No. 77-2063 (BDN-77-417)

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: Bio/dynamics, East Millstone, NJ

Title of Report: A Three-Generation Reproduction Study With  
Glyphosate in Rats.

Authors: Raymond E. Schroder, Study Director; March 31, 1981

Report Issued: July 31, 1981

Conclusions:

Glyphosate was tested in a three-generation reproduction study in the rat at the following dose levels: 0, 3, 10, and 30 mg/kg/day.

The NOEL reproductive is 10 mg/kg/day. The reproductive LEL is 30 mg/kg/day and the effect is increased incidence of focal tubular dilation of the kidney (both unilateral and bilateral combined) of male F<sub>3b</sub> weanlings (pups). The incidence of this lesion in male pups was 2/10, 5/10, 3/10, and 8/10 in the control, low-, mid-, and high-dose groups, respectively. There were no other treatment-related effects on growth, fertility, gestation, lactation indices, pup survival, pup body weight, organ weights, or histopathology in adults and pups up to 30 mg/kg/day (HDT). The systemic NOEL is 30 mg/kg/day.

Classification: Core-Minimum

Special Review Criteria (40 CFR 154.7): N/A

00059

009614

Review:

A Three-Generation Reproduction Study With Glyphosate in Rats (Bio/dynamics Project No. 77-2063 (BDN-77-417); July 31, 1981).

Test Material - Technical Glyphosate; 98.7% purity; Lot No. XHJ-64; white powder.

Animals - Sprague-Dawley young rats, age 28 days, were obtained from Charles River Breeding Laboratories, Inc., Wilmington, MA 01887. The rats were 43 days old at study initiation. They were individually caged (except during mating and lactation) and received Purina Lab Chow #5001 and tap water ad libitum. Nesting material - hardwood shavings - was added to cages on Day 19 of gestation and changed when wet or soiled through Day 14 of lactation.

Methods:

1. Mating - One male and two females of equivalent dose levels were caged together nightly until a sign of mating (sperm and/or copulation plug in the vagina) was observed or until 15 days had elapsed with no evidence of mating. Care was taken during matings of F<sub>1</sub> and F<sub>2</sub> generations to avoid brother-sister mating. The day on which evidence of mating was observed was defined as Day 0 of gestation.


2. Experimental Outline

| Group | Dose Level<br>(mg/kg/day) | No. of Adults<br>Initially                          |         | No. of Matings<br>Per Generation<br>(F <sub>0</sub> , F <sub>1</sub> , F <sub>2</sub> ) | Adults-Offspring<br>Gross Post-<br>mortem<br>Examination | Histopathology                                                       |         |
|-------|---------------------------|-----------------------------------------------------|---------|-----------------------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------------------|---------|
|       |                           | Assigned to Mate                                    |         |                                                                                         |                                                          | (F <sub>0</sub> , F <sub>1</sub> , F <sub>2</sub> , F <sub>3</sub> ) |         |
|       |                           | (F <sub>0</sub> , F <sub>1</sub> , F <sub>2</sub> ) |         |                                                                                         |                                                          |                                                                      |         |
|       |                           | Males                                               | Females |                                                                                         |                                                          | Males                                                                | Females |
| I     | 0                         | 12                                                  | 24      | 2                                                                                       | All                                                      | 10                                                                   | 10      |
| II    | 3                         | 12                                                  | 24      | 2                                                                                       | All                                                      | -                                                                    | -       |
| III   | 10                        | 12                                                  | 24      | 2                                                                                       | All                                                      | -                                                                    | -       |
| IV    | 30                        | 12                                                  | 24      | 2                                                                                       | All                                                      | 10                                                                   | 10      |

00050

3. A schematic diagram of the reproduction study is shown below:

Schematic Diagram  
3-Generation Reproduction Study



\*All parental group contained 12 males and 24 females at the start of the growth period.

\*\*Histopathology on 10 male/10 female control and high-dose group parents.

4. The test substance (diphosate) was added in the basal diet, based on weekly measurements of body weight and food consumption, to achieve dietary levels of 3, 10, and 30 mg/kg/day. The control rats received basal diet only. Assays for stability, homogeneity, and concentration were acceptable.
5. Body weights and food consumption were measured during the growth period (63 days), and rest periods, Days 0, 6, 15, and 20 of gestation, and Days 0, 4, 14, and 21 of lactation. Animals were observed twice daily for toxicity and mortality.
6. Tissues listed below were taken from all parents (F<sub>0</sub>, F<sub>1</sub>, F<sub>2</sub>) and from 10/sex/group (chosen randomly) of the F<sub>3b</sub> weanlings. All tissues were preserved in 10 percent

009614

neutral buffered formalin. (Eyes and testes were placed initially in Bouin's solution.)

Tissues Preserved:

|                             |                           |
|-----------------------------|---------------------------|
| Adrenal (2)                 | Mammary gland             |
| Aorta                       | (right inguinal)          |
| Bone and bone marrow        | Pancreas                  |
| (sternal)                   | Pituitary                 |
| Brain (2 longitudinal       | Salivary gland            |
| sections                    | Skeletal muscle (biceps   |
| Eye (2) with optic          | femoris with right        |
| nerve and Harderian         | sciatic nerve)            |
| gland                       | Skin                      |
| Gonads                      | Spinal cord (cervical and |
| Heart                       | lumbar)                   |
| Intestine                   | Spleen                    |
| colon                       | Stomach                   |
| duodenum                    | Thyroid and Parathyroid   |
| ileum                       | (attached to trachea      |
| Kidney (2)                  | and esophagus)            |
| Liver (2 sections)          | Urinary bladder           |
| Lung (section with mainstem | Uterus/prostate           |
| bronchi)                    | Gross lesions             |
| Lymph nodes (mesenteric)    | Tissue masses             |
|                             | Thymus                    |

7. Organs Weighed - The following organs were weighed from all parents sacrificed after weaning of the second litters and from 80 F<sub>3b</sub> weanlings (10 males and 10 females per group) with tissues preserved:

|          |           |
|----------|-----------|
| Adrenals | Spleen    |
| Gonads   | Liver     |
| Kidneys  | Heart     |
| Brain    | Pituitary |

8. Histology and Histopathology - Section of all tissues listed above (Tissues Preserved) were prepared and examined microscopically from 10 male and 10 female animals from control and high-dose groups of the following:

Parents: F<sub>0</sub>, F<sub>1</sub>, and F<sub>2</sub>  
 Offspring: F<sub>3b</sub>

Any tissue masses observed in any animals were also examined.

00062

9. Statistical Analysis - Litter examination data, growth and rest period body weight and food consumption data, and maternal body weight (gestation and lactation) data were compared to the control. Statistically significant differences from control are indicated in mean tables and appendices and were significant at  $p < 0.05$ . Statistical methods used in the study are attached.

Results:

A. Body Weight and Food Consumption

Parental Animals ( $F_0$ ), ( $F_1$ ), and ( $F_2$ )

Mean body weights of parental animals during the growth, rest, gestation, and lactation periods were comparable between control and treated groups for each generation throughout the study.

There were no compound-related effects on parental body weight data. Similarly mean food consumption data were considered comparable between control and treated groups of both sexes during the growth, rest, gestation, and lactation periods for each generation.

009614

B. Mating, Pregnancy, and Fertility IndicesF<sub>0</sub> Generation

## Mortality, Mating, Pregnancy, and Fertility Rates

| Group<br>mg/kg/day | Total<br>Number Exposed |       | Mortality <sup>a</sup> |   |          |   | Mating               |   |                    |   | Pregnancy            |   | Fertility                |   |
|--------------------|-------------------------|-------|------------------------|---|----------|---|----------------------|---|--------------------|---|----------------------|---|--------------------------|---|
|                    |                         |       | Females                |   | Males    |   | Females <sup>b</sup> |   | Males <sup>c</sup> |   | Females              |   | Males                    |   |
|                    | Females                 | Males | No. Dead               | % | No. Dead | % | Mated / Total        | % | Mated / Total      | % | Pregnant / No. Mated | % | Impregnating / No. Mated | % |

F<sub>0</sub> Mating (for F<sub>1a</sub> generation)

|           |    |    |   |     |   |     |        |      |       |       |        |      |       |       |
|-----------|----|----|---|-----|---|-----|--------|------|-------|-------|--------|------|-------|-------|
| I<br>0    | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 20/24  | 83.3 | 11/12 | 91.7  | 19/20  | 95.0 | 11/11 | 100.0 |
| II<br>3   | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 22/24  | 91.7 | 12/12 | 100.0 | 21/22  | 95.5 | 12/12 | 100.0 |
| III<br>10 | 24 | 12 | 1 | 4.2 | 0 | 0.0 | 19/24* | 79.2 | 10/12 | 83.3  | 16*/19 | 84.2 | 9/10  | 90.0  |
| IV<br>30  | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 21/24  | 87.5 | 11/12 | 91.7  | 19/21  | 90.5 | 11/11 | 100.0 |

F<sub>0</sub> Mating (for F<sub>1b</sub> generation)

|           |    |    |   |     |   |     |        |      |       |       |        |      |       |       |
|-----------|----|----|---|-----|---|-----|--------|------|-------|-------|--------|------|-------|-------|
| I<br>0    | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 20/24  | 83.3 | 11/12 | 91.7  | 19/20  | 95.0 | 11/11 | 100.0 |
| II<br>3   | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 23/24  | 95.8 | 12/12 | 100.0 | 19/23  | 82.6 | 12/12 | 100.0 |
| III<br>10 | 24 | 12 | 1 | 4.3 | 0 | 0.0 | 17/23* | 73.9 | 11/12 | 91.7  | 12*/17 | 70.6 | 10/11 | 90.9  |
| IV<br>30  | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 22/24  | 91.7 | 11/12 | 91.7  | 18/22  | 81.8 | 10/11 | 90.9  |

There were no dose-related effects in female mating or pregnancy ratios in the F<sub>1a</sub> and F<sub>1b</sub> generations, although the female mating and pregnancy ratios at 10 mg/kg/day were lower than control values. The findings, however, were not dose-related and are not compound-related.

00364

009614

F<sub>1</sub> Generation

## Mortality, Mating, Pregnancy, and Fertility Rates

| Group | Total<br>Number Exposed |  | Mortality <sup>a</sup> |   |          |   | Mating                    |   |                           |   | Pregnancy          |   | Fertility                            |   |
|-------|-------------------------|--|------------------------|---|----------|---|---------------------------|---|---------------------------|---|--------------------|---|--------------------------------------|---|
|       |                         |  | Females                |   | Males    |   | Females                   |   | Males                     |   | Females            |   | Males                                |   |
|       | mg/kg/day               |  | No. Dead               | % | No. Dead | % | Mated <sup>b</sup> /Total | % | Mated <sup>c</sup> /Total | % | Pregnant/No. Mated | % | Impregnating <sup>d</sup> /No. Mated | % |

F<sub>1</sub> Mating (for F<sub>2a</sub> generation)

|     |    |    |   |     |   |     |       |      |       |       |       |       |       |       |
|-----|----|----|---|-----|---|-----|-------|------|-------|-------|-------|-------|-------|-------|
| I   | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 18/24 | 75.0 | 10/12 | 83.3  | 18/18 | 100.0 | 10/10 | 100.0 |
| 0   |    |    |   |     |   |     |       |      |       |       |       |       |       |       |
| II  | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 23/24 | 95.8 | 12/12 | 100.0 | 20/23 | 87.0  | 11/12 | 91.7  |
| 3   |    |    |   |     |   |     |       |      |       |       |       |       |       |       |
| III | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 18/24 | 75.0 | 9/12  | 75.0  | 17/18 | 94.4  | 9/9   | 100.0 |
| 10  |    |    |   |     |   |     |       |      |       |       |       |       |       |       |
| IV  | 23 | 12 | 1 | 4.2 | 0 | 0.0 | 19/23 | 82.6 | 11/12 | 91.7  | 18/19 | 94.7  | 10/11 | 90.9  |
| 30  |    |    |   |     |   |     |       |      |       |       |       |       |       |       |

F<sub>1</sub> Mating (for F<sub>2b</sub> generation)

|     |    |    |   |     |   |     |       |      |       |       |       |      |       |       |
|-----|----|----|---|-----|---|-----|-------|------|-------|-------|-------|------|-------|-------|
| I   | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 17/24 | 70.8 | 9/12  | 75.0  | 15/17 | 88.2 | 9/9   | 100.0 |
| 0   |    |    |   |     |   |     |       |      |       |       |       |      |       |       |
| II  | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 19/24 | 79.2 | 10/12 | 83.3  | 15/19 | 78.9 | 9/10  | 90.0  |
| 3   |    |    |   |     |   |     |       |      |       |       |       |      |       |       |
| III | 24 | 12 | 0 | 0.0 | 0 | 0.0 | 17/24 | 70.8 | 10/12 | 83.3  | 14/17 | 82.4 | 10/10 | 100.0 |
| 10  |    |    |   |     |   |     |       |      |       |       |       |      |       |       |
| IV  | 24 | 12 | 1 | 4.3 | 0 | 0.0 | 19/23 | 82.6 | 12/12 | 100.0 | 14/19 | 73.9 | 10/12 | 83.3  |
| 30  |    |    |   |     |   |     |       |      |       |       |       |      |       |       |

00005

009614

F<sub>2</sub> Generation

## Mortality, Mating, Pregnancy, and Fertility Rates

| Group                                                  | Total<br>Number Exposed |       | Mortality <sup>a</sup> |     |          |     | Mating                    |       |                           |       | Pregnancy          |       | Fertility                            |       |
|--------------------------------------------------------|-------------------------|-------|------------------------|-----|----------|-----|---------------------------|-------|---------------------------|-------|--------------------|-------|--------------------------------------|-------|
|                                                        |                         |       | Females                |     | Males    |     | Females                   |       | Males                     |       | Females            |       | Males                                |       |
|                                                        | Females                 | Males | No. Dead               | %   | No. Dead | %   | Mated <sup>b</sup> /Total | %     | Mated <sup>c</sup> /Total | %     | Pregnant/No. Mated | %     | Impregnating <sup>d</sup> /No. Mated | %     |
| F <sub>2</sub> Mating (for F <sub>3a</sub> generation) |                         |       |                        |     |          |     |                           |       |                           |       |                    |       |                                      |       |
| I<br>0                                                 | 24                      | 12    | 0                      | 0.0 | 0        | 0.0 | 24/24                     | 100.0 | 12/12                     | 100.0 | 23/24              | 95.8  | 12/12                                | 100.0 |
| II<br>5                                                | 24                      | 12    | 1                      | 4.2 | 0        | 0.0 | 20/24                     | 83.3  | 10/12                     | 83.3  | 20/20              | 100.0 | 10/10                                | 100.0 |
| III<br>10                                              | 24                      | 12    | 0                      | 0.0 | 0        | 0.0 | 20/24                     | 83.3  | 10/12                     | 83.3  | 16/20              | 80.0  | 8/10                                 | 80.0  |
| IV<br>50                                               | 24                      | 12    | 0                      | 0.0 | 0        | 0.0 | 18/24                     | 75.0* | 10/12                     | 83.3  | 17/18              | 94.4  | 10/10                                | 100.0 |
| F <sub>2</sub> Mating (for F <sub>3b</sub> generation) |                         |       |                        |     |          |     |                           |       |                           |       |                    |       |                                      |       |
| I<br>0                                                 | 24                      | 12    | 0                      | 0.0 | 0        | 0.0 | 23/24                     | 95.8  | 12/12                     | 100.0 | 22/23              | 95.7  | 11/12                                | 91.7  |
| II<br>5                                                | 23                      | 12    | 0                      | 0.0 | 0        | 0.0 | 19/23                     | 82.6  | 10/12                     | 83.3  | 16/19              | 84.2  | 10/12                                | 83.3  |
| III<br>10                                              | 24                      | 11    | 0                      | 0.0 | 1        | 8.3 | 20/24                     | 83.3  | 10/11                     | 90.9  | 16/20              | 80.0  | 9/10                                 | 90.0  |
| IV<br>30                                               | 24                      | 12    | 0                      | 0.0 | 0        | 0.0 | 21/24                     | 87.5  | 11/12                     | 91.7  | 19/21              | 90.5  | 10/11                                | 90.9  |

\*p &lt; 0.05

Over the three generations, there were no dose-related effects to indicate a compound-related effect on mating, pregnancy, and fertility indices for either sex. The statistically significant decrease in the high-dose females mating index (75.0% in high-dose vs. 100% in controls) for the F<sub>3a</sub> litters was not shown to be a consistent finding, since the F<sub>3b</sub> litters produced by the high-dose group females resulted from a mating index of 87.5 percent (high-dose) in comparison to 95.8 percent in controls. Additionally, pregnancy rates of the F<sub>2</sub> generation were unaffected by treatment. Also, the

00006



009614

mating indices of the  $F_0$  and  $F_1$  females were comparable between control and test groups.

C. Gestation Length, Offspring Viability, Survival, and Growth (Body Weight)

$F_0$  Generation

| Group                            | Mean Gestation Length<br>Days | Mean No. Pups at Birth |      |       | Pup Viability Index at Birth |      | Mean No. Pups Weaned/Litter | Postnatal Offspring Survival |      |                      |        | Index of Litters <sup>b</sup> Weaned |       | Mean Weights of Live Offspring (grams) |     |      |
|----------------------------------|-------------------------------|------------------------|------|-------|------------------------------|------|-----------------------------|------------------------------|------|----------------------|--------|--------------------------------------|-------|----------------------------------------|-----|------|
|                                  |                               |                        |      |       | Live/Total Born              | %    |                             | 0-4                          |      | 4-21                 |        | No.                                  | %     | Days: 0                                | 4   | 21   |
|                                  |                               |                        |      |       |                              |      |                             | No.                          | %    | No.                  | %      |                                      |       |                                        |     |      |
|                                  |                               |                        |      |       |                              |      |                             |                              |      |                      |        |                                      |       |                                        |     |      |
| mg/kg/day                        |                               | Live                   | Dead | Total | No.                          | %    | Days:                       | No.                          | %    | No.                  | %      | No.                                  | %     | Days: 0                                | 4   | 21   |
| F <sub>0</sub> → F <sub>1a</sub> |                               |                        |      |       |                              |      |                             |                              |      |                      |        |                                      |       |                                        |     |      |
| I<br>0                           | 22.1                          | 11.5                   | 0.1  | 11.6  | 218/220                      | 99.1 | 10.7                        | 210/218                      | 96.3 | 192/195 <sup>c</sup> | 98.5   | 19/19                                | 100.0 | 6.0                                    | 9.9 | 41.  |
| II<br>3                          | 21.8                          | 12.8                   | 0.1  | 12.9  | 268/271                      | 98.9 | 12.4                        | 251/268                      | 93.7 | 247/251              | 98.4   | 20/21                                | 95.2  | 5.8                                    | 9.3 | 37.  |
| III<br>10                        | 21.8                          | 12.3                   | 0.3  | 12.5  | 196/200                      | 98.0 | 11.9                        | 194/196                      | 99.0 | 192/194              | 99.0   | 16/16                                | 100.0 | 5.9                                    | 9.4 | 39.  |
| IV<br>30                         | 21.8                          | 11.6                   | 0.1  | 11.7  | 221/222                      | 99.5 | 11.3                        | 217/221                      | 98.7 | 215/217              | 99.1   | 19/19                                | 100.0 | 6.0                                    | 9.6 | 39.  |
| F <sub>0</sub> → F <sub>1b</sub> |                               |                        |      |       |                              |      |                             |                              |      |                      |        |                                      |       |                                        |     |      |
| I<br>0                           | 22.0                          | 11.7                   | 0.2  | 11.9  | 223/226                      | 98.7 | 11.3                        | 218/223                      | 97.8 | 215/218              | 98.6   | 19/19                                | 100.0 | 6.1                                    | 9.9 | 40.9 |
| II<br>3                          | 21.8                          | 12.2                   | 0.6  | 12.8  | 232/243                      | 95.5 | 11.4                        | 223/232                      | 96.1 | 206/223              | 92.4** | 18/19                                | 94.7  | 6.1                                    | 9.7 | 43.7 |
| III<br>10                        | 22.0                          | 12.8                   | 0.3  | 13.1  | 153/157                      | 97.5 | 10.9                        | 145/153                      | 94.8 | 120/145              | 82.8** | 11/12                                | 91.7  | 5.8                                    | 9.0 | 37.7 |
| IV<br>30                         | 21.9                          | 12.6                   | 0.3  | 12.8  | 226/231                      | 97.8 | 11.4                        | 225/226                      | 99.6 | 194/214 <sup>d</sup> | 90.7** | 17/17 <sup>e</sup>                   | 100.0 | 6.2                                    | 9.9 | 36   |

Significantly different from control: \* $p < 0.05$ ; \*\* $p < 0.01$

009614

F<sub>1</sub> Generation

| Group                            | Mean Gestation Length | Mean No. Pups at Birth |      |       | Pup Viability Index at Birth |       | Mean No. Pups Weaned/Litter | Days: | Postnatal Offspring Survival |        |         |       | Index of Litters Weaned <sup>b</sup> |       | Mean Weights of Live Offspring (grams) |      |         |   |    |
|----------------------------------|-----------------------|------------------------|------|-------|------------------------------|-------|-----------------------------|-------|------------------------------|--------|---------|-------|--------------------------------------|-------|----------------------------------------|------|---------|---|----|
|                                  |                       |                        |      |       | Live/Total Born              | %     |                             |       | 0-4                          |        | 4-21    |       | No.                                  | %     | No.                                    | %    | Days: 0 | 4 | 21 |
|                                  |                       |                        |      |       |                              |       |                             |       | No.                          | %      | No.     | %     |                                      |       |                                        |      |         |   |    |
| mg/kg/day                        | Days                  | Live                   | Dead | Total | No.                          | %     |                             |       | No.                          | %      | No.     | %     | No.                                  | %     |                                        |      |         |   |    |
| F <sub>1</sub> → F <sub>2a</sub> |                       |                        |      |       |                              |       |                             |       |                              |        |         |       |                                      |       |                                        |      |         |   |    |
| I<br>0                           | 21.9                  | 12.0                   | 0.2  | 12.2  | 216/219                      | 98.6  | 11.7                        |       | 201/216                      | 93.1   | 199/201 | 99.0  | 17/18                                | 94.4  | 5.8                                    | 9.1  | 41.0    |   |    |
| II<br>3                          | 21.8                  | 11.8                   | 0.0  | 11.8  | 236/236                      | 100.0 | 11.6                        |       | 231/236                      | 97.9*  | 231/231 | 100.0 | 20/20                                | 100.0 | 6.0                                    | 9.7  | 43.4    |   |    |
| III<br>10                        | 21.9                  | 12.7                   | 0.0  | 12.7  | 216/216                      | 100.0 | 12.4                        |       | 214/216                      | 99.1** | 211/214 | 98.6  | 17/17                                | 100.0 | 6.0                                    | 9.1  | 39.7    |   |    |
| IV<br>30                         | 22.0                  | 11.5                   | 0.4  | 11.9  | 207/214                      | 96.7  | 11.1                        |       | 206/207                      | 99.5** | 200/205 | 97.1  | 18/18                                | 100.0 | 6.2                                    | 9.4  | 40.3    |   |    |
| F <sub>1</sub> → F <sub>2b</sub> |                       |                        |      |       |                              |       |                             |       |                              |        |         |       |                                      |       |                                        |      |         |   |    |
| I<br>0                           | 21.9                  | 12.4                   | 0.4  | 12.8  | 186/192                      | 96.9  | 11.9                        |       | 178/186                      | 95.7   | 178/178 | 100.0 | 15/15                                | 100.0 | 5.9                                    | 9.4  | 41.1    |   |    |
| II<br>3                          | 21.9                  | 12.5                   | 0.4  | 12.9  | 187/193                      | 96.9  | 12.7                        |       | 166/187                      | 88.8*  | 165/166 | 99.4  | 13/15                                | 86.7  | 5.7                                    | 9.2  | 41.1    |   |    |
| III<br>10                        | 22.1                  | 13.1                   | 0.2  | 13.4  | 184/187                      | 98.4  | 12.7                        |       | 181/184                      | 98.4   | 178/181 | 98.3  | 14/14                                | 100.0 | 5.8                                    | 9.5  | 41.3    |   |    |
| IV<br>30                         | 22.1                  | 11.3                   | 0.3  | 11.6  | 147/151                      | 97.4  | 11.1                        |       | 144/147                      | 98.0   | 144/144 | 100.0 | 13/13                                | 100.0 | 6.4                                    | 10.3 | 41.3    |   |    |

Significantly different from control: \*p &lt; 0.05; \*\*p &lt; 0.01

00008

009614

F<sub>2</sub> Generation

| Group     | Mean Gestation Length | Mean Pups at Birth |      | Pup Viability Index at Birth |       | Mean No. Pups Weaned/Litter | Postnatal Offspring Survival |     |      |     | Index of Litters Weaned |              | Mean Weights of Live Offspring (grams) |         |   |    |
|-----------|-----------------------|--------------------|------|------------------------------|-------|-----------------------------|------------------------------|-----|------|-----|-------------------------|--------------|----------------------------------------|---------|---|----|
|           |                       |                    |      | Live/Total Born              | No. % |                             | 0-4                          |     | 4-21 |     | No. %                   | Days: 0 4 21 |                                        |         |   |    |
|           |                       |                    |      |                              |       |                             | No.                          | %   | No.  | %   |                         |              |                                        |         |   |    |
|           |                       |                    |      |                              |       |                             |                              |     |      |     |                         |              |                                        |         |   |    |
| mg/kg/day | Days                  | Live               | Dead | Total                        | No.   | %                           | Days:                        | No. | %    | No. | %                       | No.          | %                                      | Days: 0 | 4 | 21 |

F<sub>1</sub> → F<sub>2a</sub>

|           |      |      |     |      |         |        |      |  |         |       |         |       |       |       |     |     |      |
|-----------|------|------|-----|------|---------|--------|------|--|---------|-------|---------|-------|-------|-------|-----|-----|------|
| I<br>0    | 21.9 | 11.7 | 0.2 | 11.9 | 268/273 | 98.2   | 11.0 |  | 266/268 | 99.3  | 254/266 | 95.5  | 23/23 | 100.0 | 6.0 | 9.5 | 37.1 |
| II<br>3   | 22.0 | 11.1 | 0.9 | 12.0 | 222/240 | 92.5** | 10.6 |  | 219/222 | 98.6  | 100/219 | 86.6* | 18/19 | 94.7  | 6.1 | 9.4 | 36.8 |
| III<br>10 | 21.9 | 12.6 | 0.1 | 12.8 | 202/204 | 99.0   | 11.8 |  | 202/202 | 100.0 | 188/202 | 93.1  | 16/16 | 100.0 | 6.0 | 9.5 | 37.3 |
| IV<br>30  | 21.9 | 11.8 | 0.3 | 12.1 | 200/205 | 97.6   | 11.0 |  | 198/200 | 99.0  | 187/198 | 94.4  | 17/17 | 100.0 | 6.3 | 9.3 | 36.7 |

F<sub>1</sub> → F<sub>2b</sub>

|           |      |      |     |      |         |      |      |  |         |      |         |      |       |       |     |     |      |
|-----------|------|------|-----|------|---------|------|------|--|---------|------|---------|------|-------|-------|-----|-----|------|
| I<br>0    | 21.9 | 11.2 | 0.2 | 11.5 | 247/252 | 98.0 | 11.3 |  | 241/247 | 97.6 | 237/247 | 98.3 | 21/22 | 95.5  | 5.9 | 8.8 | 38.7 |
| II<br>3   | 21.9 | 12.3 | 0.4 | 12.7 | 197/203 | 97.0 | 12.7 |  | 192/197 | 97.5 | 191/192 | 99.5 | 15/16 | 93.8  | 5.8 | 9.0 | 39.6 |
| III<br>10 | 22.1 | 13.0 | 0.1 | 13.1 | 208/210 | 98.0 | 12.4 |  | 202/208 | 97.1 | 198/202 | 98.0 | 16/16 | 100.0 | 6.1 | 9.5 | 39.3 |
| IV<br>30  | 21.9 | 9.8  | 0.5 | 10.4 | 187/197 | 94.9 | 9.9  |  | 183/187 | 97.9 | 178/185 | 97.3 | 13/19 | 94.7  | 6.3 | 8.1 | 38.5 |

Significantly different from control: \*p &lt; 0.05; \*\*p &lt; 0.01

00069

The statistically significant decreases in Day 4 to 21 pup survival at all dose levels in the F<sub>1b</sub> litter were attributed to high pup mortality within one or more litters at each dose level.

"As stated in the report, in the low-dose group the lower pup survival was attributed to one female (No. 1404) that experienced complete litter mortality (litter contained 14 live pups at Day 4). In the mid-dose group, one female (No. 617) died on Day 7 of lactation and all seven pups in her litter died during the Day 4 to 7 lactation interval. Additionally, three mid-dose litters (females No. 609, 610, and 620) lost five or more pups from their litters during the Day 4 to 21 lactation interval. In the high-dose group, female No. 815 lost 9 of 12 pups during the Day 4 to 21 lactation interval."

Pup survival between Day 4 and 21 in the F<sub>1</sub> and F<sub>2</sub> generations was comparable between control and treated groups. Therefore, the findings in the F<sub>1b</sub> litters were not consistent and were not considered compound-related.

There were no compound-related effects on pup body weight or sex ratio for any of the litters of the F<sub>0</sub>, F<sub>1</sub>, and F<sub>2</sub> generations.

- D. Pathology - With respect to the F<sub>3b</sub> weanlings (pups), there were no compound-related effects in organ weights. The mean liver weight to body and brain weight ratios of the F<sub>2</sub> parental females of all treated groups were significantly lower than control values, but the differences were not dose-related. These findings were not considered compound-related, since similar effects in F<sub>0</sub> and F<sub>1</sub> parental animals were not observed and there were no histopathological findings associated with the lower liver weight results in F<sub>2</sub> adults. The incidence of tubular dilation of the kidney in F<sub>3b</sub> male pups showed a significant increase at 30 mg/kg/day. The results are shown below:

|                          | Control | 3    | 10  | 30   |
|--------------------------|---------|------|-----|------|
| <u>Kidney</u>            |         |      |     |      |
| Focal Tubular Dilatation |         |      |     |      |
| - Unilateral             | 2/10    | 3/10 | 2/9 | 7/10 |
| - Bilateral              | 0/10    | 2/10 | 1/9 | 1/10 |

009614

The kidney microscopic finding in high-dose male F<sub>3b</sub> pups is considered compound-related.

There were no other compound-related histopathological findings in parental animals or F<sub>3b</sub> pups examined histologically.

The NOEL is 10 mg/kg/day.

The study is classified as core-minimum since there were three generations with two litters per generation, which exceeds the minimum requirements for a reproduction study. Although there often were less than 20 pregnant rats/dose, this deficiency is offset by the additional generation produced in this study. There also was a sufficient number of animals for statistical analyses to be conducted. Although only 10 animals/sex/dose were examined histopathologically, they included animals from the F<sub>0</sub>, F<sub>1</sub>, and F<sub>2</sub> adults (rather than just F<sub>1</sub> adults in current minimum studies) and also included 10/sex/dose of F<sub>3b</sub> pups. For these reasons, the study is core-minimum.

Attachments

00071

009614

62812:I:Dykstra:LHEL-1:KEVRIC:04/12/91:PERM:TJK/CL:WO:EK:CL  
R:62818:Dykstra:LHED-1:KEVRIC:4/19/91:PERM:EK  
R:62827:Dykstra:LHEL-1:KEVRIC:05/13/91:PERM:DD:WO:DD

00072

Page \_\_\_\_\_ is not included in this copy.

Pages 73 through 76 are not included.

---

The material not included contains the following type of information:

- \_\_\_\_\_ Identity of product inert ingredients.
  - \_\_\_\_\_ Identity of product impurities.
  - \_\_\_\_\_ Description of the product manufacturing process.
  - \_\_\_\_\_ Description of quality control procedures.
  - \_\_\_\_\_ Identity of the source of product ingredients.
  - \_\_\_\_\_ Sales or other commercial/financial information.
  - \_\_\_\_\_ A draft product label.
  - \_\_\_\_\_ The product confidential statement of formula.
  - \_\_\_\_\_ Information about a pending registration action.
  - ☒ FIFRA registration data.
  - \_\_\_\_\_ The document is a duplicate of page(s) \_\_\_\_\_.
  - \_\_\_\_\_ The document is not responsive to the request.
- 

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

---

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/11/91*  
Toxicology Branch I - IRS (H7509C)  
*for* Secondary Reviewer: Roger Gardner, Section Head *Samela M. Hawley 5/14/91*  
Toxicology Branch I - IRS (H7509C)

009614

DATA EVALUATION REPORT

Study Type: Pharmacokinetics - Not a  
Mutagenicity Study

TOX Chem. No.: 661A

Accession No.: 251737

MRID No.: 00132685

Test Material:  $C^{14}$ -Glyphosate; Specific Activity 5 mCi/mole

Synonyms: Roundup

Study Number: 830109; DMEH No. ML-83-218

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: Environmental Health Lab, St. Louis, MO

Title of Report: A Study of the Plasma and Bone Marrow Levels of  
Glyphosate Following the Intraperitoneal  
Administration in the Rat.

Author: W.P. Ridley

Report Issued: October 24, 1983

Conclusions:

Thirty minutes following intraperitoneal (ip) administration of [ $^{14}C$ ]-glyphosate to male and female Charles River Sprague-Dawley rats at 1150 mg/kg, the concentration of radiolabel present in bone marrow was  $267 \pm 31$  and  $413 \pm 39$  ppm, respectively (equivalent to 0.0044 and 0.0072 percent of the dose). Assuming first order kinetics, the decrease in radioactivity occurred with a half-life of 7.6 and 4.2 hours from the males and females, respectively. Similarly, the half-lives of radiolabel in the plasma were approximately 1 hour in both sexes.

Classification: Acceptable

Special Review Criteria (40 CFR 154.7): N/A

Note: The DER is based on parts of a Dynamac review.

00077



009614

Review:

Quality Assurance Statement - Present, signed, and dated October 20, 1983.

Test Material - The test material used was a mixture of [ $^{14}\text{C}$ -methyl] N-(phosphonomethyl) glycine sodium salt, and the protonated acid of the unlabeled test material. Radiolabeled glyphosate had a specific activity of 5 mCi/mmol and a radiochemical purity of 98 percent, whereas the purity of unlabeled glyphosate was 98.7 percent.

Protocol

1. Nine male and nine female Crl:CD Br rats were obtained from Charles River Laboratories, Wilmington, MA. The animals were acclimatized to laboratory conditions for a period of 7 days, then placed in stainless steel metabolism cages for 4 days prior to dosing, and for the duration of the study. Purina Rat Chow and water were available *ad libitum*. The rats were fasted for a period of 22 to 24 hours prior to dosing. The animals were 8 to 9 weeks old and the average weight of the male was 264 g and of females 186.0 g at dosing.
2. A dosing solution containing 12.25 g and 5.487 mg of the unlabeled and [ $^{14}\text{C}$ ] labeled glyphosate, respectively, in Hank's Balanced Salt Solution was prepared. The final pH of this dosing solution was adjusted to 7.18 in the final volume of about 70 mL. The specific activity was determined to be 29.8 dpm/ $\mu\text{g}$  glyphosate based upon the protonated acid weight.
3. The rats were dosed by ip injection and the precise amount administered was calculated from the difference in weight of the syringe and needle before and after dosing. The males received  $1150 \pm 3.3$  mg/kg containing  $9.013 \pm 0.09 \times 10^6$  dpm and the females received  $1150 \pm 7.5$  mg/kg containing  $6.394 \pm 0.20 \times 10^6$  dpm of test material.
4. Blood samples were collected by orbital sinus puncture from six males and six females 15 minutes after dosing. Additional samples were collected from three animals of each sex at approximately 0.5, 1, 2, 4, 6, and 10 hours after dosing. No more than three blood samples were collected from any one rat during that period. The whole blood samples were centrifuged and 0.1 mL of plasma were radioassayed in 15 mL of Instagel.

00078

009614

At approximately 0.5, 4, and 10 hours after dosing, three males and three females were sacrificed by cervical dislocation, and the bone marrow from both the right and left femur of each animal collected. The bone marrows were weighed, digested in soluene-350 at 50 °C for 5 to 6 hours, then allowed to sit at room temperature overnight. The samples were decolorized, 15 mL of Dimilune-30 added, and then were allowed to equilibrate to temperature and light in the liquid - scintillation counter prior to counting. Counting efficiencies were determined by means of an external standard and corrections were made for quenching. The results were reported both in dpm/g tissue and  $\mu\text{g}$  glyphosate equivalents/g tissue (ppm).

#### Results:

A maximum concentration of radiolabeled material in male and female plasma was noted 30 minutes after ip administration. This corresponded to a level of  $1867 \pm 160$  ppm and  $2019 \pm 83$  ppm of glyphosate and/or its metabolites in males and females, respectively. The concentration of radiolabel in plasma decreased subsequently. Linear regression analysis of the data indicated that the decrease in radioactivity occurred with a half-life of approximately 0.99 and 1.0 hours in males and females, respectively.

The concentration of radiolabel measured in the bone marrow 30 minutes after administration was  $267 \pm 31$  and  $413 \pm 39$  ppm for males and females, respectively. Assuming first order kinetics, the decrease in radioactivity occurred with a half-life of 7.6 and 4.2 hours for the males and females, respectively.

#### Discussion:

The study was conducted in order to "confirm that glyphosate" reaches the bone marrow following ip injection. The amounts reaching the bone marrow were considered by the authors sufficient to justify cytogenetic evaluation. However, identification of the radiolabeled material in the bone marrow was not conducted, and only 0.0044 (13  $\mu\text{g}/\text{rat}$ ) and 0.0072 (15.4  $\mu\text{g}/\text{rat}$ ) percent of the dose administered ip reached the bone marrow in males and females, respectively.

#### Conclusion:

Thirty minutes following ip administration of [ $^{14}\text{C}$ ]-glyphosate to male and female Charles River rats at 1150 mg/kg, the concentration of radiolabel present in the bone marrow was  $267 \pm 31$  and  $413 \pm 39$  ppm, respectively (equivalent to 0.0044 and 0.0072 percent of the dose). Assuming first order kinetics, the decrease in radioactivity occurred with a half-life of 7.6 and 4.2 hours for

00279

the males and females, respectively. Similarly, the half-lives of radiolabel in the plasma were approximately 1 hour in both sexes.

Core Classification: Acceptable

009614

00000

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/11/91*  
Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Pamela M. Harty 5/14/91*  
Toxicology Branch I - IRS (H7509C)

009614

DATA EVALUATION REPORT

Study Type: 84-2a - Gene Mutation  
Mammalian Cell

TOX Chem. No.: 661A

Accession No.: 251737

MRID No.: 00132681

Test Material: Glyphosate Technical; 98.7% Purity; Lot No. XHJ-64

Synonyms: Sample No. T830044

Study Number: ML-83-155  
EHL No. 830079

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: Environmental Health Lab, St. Louis, MO

Title of Report: CHO/HGPRT Gene Mutation Assay With Glyphosate.

Author: A.P. Li

Report Issued: October 20, 1983

Conclusions:

Technical glyphosate did not induce a mutagenic response, with or without S9, up to limit of cytotoxicity (10 mg/mL) against standard reference mutagens. The range of glyphosate tested was 2 to 25 mg/mL.

Classification: Acceptable

Special Review Criteria (40 CFR 154.7): N/A

Note: Dr. Irving Mauer, geneticist, screened the mutagenicity assay for acceptability. The DER is based on parts of a Dynamac review.

00031

009614

Review:

Quality Assurance Statement - Present, signed, and dated October 20, 1983.

Test Material - The test material was identified as Glyphosate, a white powder, Lot No. XHJ-64, submitted to Environmental Health Laboratory (EHL) and indicated to be 98.7 percent pure. It was assigned Sample No. I830044 by EHL and stored at room temperature.

Materials and Methods:

Preparation of the Test Material - Stock solutions of glyphosate were made in Ham's F12 V medium (K.C. Biological) and neutralized to pH 7.0 to 7.4 with 1N NaOH until a clear solution was obtained. Test solutions of different concentrations were made by diluting the stock with Ham's F12 V medium on the testing day.

Controls - The positive controls were benzo(a)pyrene (B(a)p) for S9 activation and ethyl methane sulfonate (EMS). Both were obtained from Sigma Chemical Company, St. Louis, MO.

Cell Line - The cell line was the Chinese hamster ovary line, K<sub>1</sub>BH<sub>4</sub> originally obtained from A.W. Hsie\* at Oak Ridge National Laboratory. Cultures of these cells were maintained in Ham's F12 medium supplemented with 10 percent newborn calf serum as logarithmically growing monolayers. Growth was at  $37.5 \pm 2$  °C at a relative humidity of 95 percent under 5 percent CO<sub>2</sub>.

Cytotoxicity - At 18 to 24 hours before dosing,  $0.5 \times 10^6$  cells were seeded in 25 cm<sup>2</sup> plastic culture flasks; on the day of dosing the growth medium was replaced with 2.5 mL of Ham's F12 medium containing neither S9 nor serum. An equal volume of this medium containing 2X concentrations of the test material was added; the mixture was then incubated for 3 hours at  $37.5 \pm 2$  °C, and then the dosing medium was removed and the cells washed with 5 mL of Hank's balanced salt solution. The cells were removed by trypsinization and scored (3 samples of 200 cells plated for assessment on cloning efficiency). All plates were then reincubated for 7 to 9 days, and colonies that developed were fixed with 70 percent methanol, stained by 10 percent Giemsa and hand-scored. To calculate cloning efficiency (CE) and relative survival (RS), the following expressions were used.

---

\*Hsie, A.W., Li, A.P., and Machanoff, R. (1977) Mutant. Res. 45:333-342.

00002

**Mutagenesis Assays** - The  $K_1BH_4$  cells were plated the day before dosing with the test material, positive controls, or negative solvent controls. The procedure described for the cytotoxicity assay was followed, except that an additional  $10^6$  cells/10 mL were subcultured in hypoxanthine-free Ham's F12 medium, supplemented with 10 percent dialyzed newborn calf serum. Subculturing was carried out every 2 to 3 days, followed by the 7- to 9-day period allowed for phenotypic expression. After phenotypic expression, selective medium<sup>1</sup> (hypoxanthine-free Ham's F12 medium supplemented with 10  $\mu$ M 6-thioguanine (6TG) and 5 percent dialyzed newborn calf serum) was used to select for the 6TG-resistant mutant clones. A total of  $10^6$  cells were assessed for mutant development, using five 100 mm plates, each containing  $2 \times 10^5$  cells in 8 mL of selective medium. After incubation for 8 to 12 days, colonies were fixed, stained, and scored. The cloning efficiency was determined as previously described. Using the expression that follows, a mutation frequency (M.F.)<sup>2</sup> was calculated.

$$C.E. = \frac{\text{number of colonies developed}}{\text{number cells plated}}$$

$$R.S.^2 = \frac{C.E. \text{ (dosed)}}{C.E. \text{ (negative control)}}$$

**Experimental Design** - Two experiments were used to determine the mutagenicity of glyphosate. In Experiment A, three doses of test material (5, 17.5, and 22.5 mg/mL) estimated to yield 100, 50, and 10 percent survival were used in conjunction with S9 concentrations of 0, 1, 2, 5, and 10 percent. This test was to determine an initial estimate of mutagenic potential at an optimum S9 concentration. In Experiment B, five doses of test material (2, 5, 10, 10, and 20 mg/mL) estimated to yield 100, 70, 50, 20, and 10 percent survival were used. Since no mutagenicity was observed in Experiment A, no optimum S9 concentration was determined; therefore, a 5 percent S9 concentration was chosen as representative.

**Metabolic Activation** - The Aroclor 1254-induced rat liver S9 fraction was purchased from Litton Bionetics and was applied to cultures in varying amounts relative to the S9-cofactors. The S9-cofactor mix contained, in addition to different amounts of S9

<sup>1</sup>Li, A.P., Dahl, A.R., and Hill, J.O. (1982) Toxicol. Appl. Pharmacol. 64:482-485.

<sup>2</sup>R.S. was used to express cytotoxicity to the cell line;

$$M.F. = \frac{\text{Number mutant colonies}}{\text{Number cells plated}} \times \frac{1}{CE}$$

protein, 50 mM sodium phosphate (pH 7.5), 4 mM NADP, 5 mM glucose-6-phosphate, 30 mM KCl, 10 mg  $MgCl_2$ , and 10 mM  $CaCl_2$ . One mL of the S9-cofactor mix was added to 4 mL of medium for the cytotoxicity of mutagenicity assays.

**Statistics** - The method of Snee and Irr\* was used to analyze the mutagenicity data; mutant frequency values were transformed using  $Y = (X + 1)^{0.15}$  where  $Y$  is the transformed mutant frequency and  $X$  is the observed mutant frequency. Treatment data were compared to the solvent control data by the Student's t-test. Determination of dose-response relationships as linear, quadratic, or higher-order was possible by Snee/Irr analysis, and a program developed by Irr (DuPont) was incorporated into Monsanto's computer system.

### **Results:**

**Cytotoxicity Assay** - Approximately 90 percent lethality occurred at glyphosate doses between 20 and 25 mg/mL. Hence, 22.5 mg/mL and 25 mg/mL were the high dose in Experiment A and Experiment B, respectively.

In the presence of varying S9 concentrations, mutant frequencies  $\times 10^{-6}$  in the negative (medium) controls were 7.4 (0 percent), 5.9 (1 percent), 7.1 (2 percent), 4.4 (5 percent), and 9.1 (10 percent). At glyphosate doses of 5, 17.5, and 22.5 mg/mL, none of the mutant frequencies were significantly different from the control values. However, with 1 percent S9, the mutant frequencies (f)  $\times 10^{-6}$  and p-values\*\* at varying glyphosate doses were 5 mg/mL (f = 4.3, p = 0.6695), 17.9 mg/mL (f = 11.6, p = 0.3470), and 22.5 mg/mL (f = 19.1, p = 0.1796).

In the absence of S9 at various glyphosate doses, the mutant frequencies  $\times 10^{-6}$  were 2 mg/mL (f = 3.5, p = 0.1789), 5 mg/mL (f = 11.3, p = 0.9994), 10 mg/mL (f = 10.8, p = 0.6314), 15 mg/mL (f = 20.8, p = 0.5318), and 20 mg/mL (f = 10.1, p = 0.8695).

At concentrations ranging from 5 to 25 mg glyphosate/mL in the presence of 5 percent S9, mutant frequencies  $\times 10^{-6}$  varied from 5.7 (p = 0.8536) to 14.9 (p = 0.4811) compared to a control value of  $7.7 \times 10^{-6}$ .

The mutant frequency for treatment with 200  $\mu$ g EMS/mL averaged  $150 \times 10^{-6}$  compared to the negative control values of  $9.4 \times 10^{-6}$ . Using 2  $\mu$ g B(a)P/mL in varying amounts of S9 (expressed in percentage), the average mutant frequencies were  $(353 \times 10^{-6})$  (1 percent),

\*Snee, R.D. and Irr, J.D. (1981) Mutat. Res. 85:77-93.

\*\*Probability to be the same as control by the method of Snee and Irr (1981).

009614

( $186 \times 10^{-6}$ ) (2 percent), ( $99 \times 10^{-6}$ ) (5 percent), and ( $95 \times 10^{-6}$ ) (10 percent).

Discussion:

The authors concluded that glyphosate was cytotoxic to CHO cells at high concentrations, i.e.,  $> 10$  mg/mL, but that significant mutagenicity at the HGPRT locus was not produced.

Our assessment is that the authors have assayed the test material in an appropriate dose range without or with S9 activation at several concentrations, and their data showed no significant mutagenicity. Using 1 percent S9, however, a non-significant dose-related increase in the mutant frequency was seen in the glyphosate dose range of 5 to 22.5 mg/mL.

Conclusions:

The test material, 98.7 percent pure glyphosate, did not produce a significant mutagenic response either with or without S9 activation under the conditions of this study.

Classification: Acceptable

00005



009614

62815:I:Draft:Dykstra:LHED-3:KEVRIC:04/19/91:05/17/91:CL:WO:EK:DD  
R:62898:Dykstra:LHED-3:KEVRIC:04/25/91:05/25/91:CL

00000

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/13/91*  
Section I, Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Pamela M. Hanley 5/14/91*  
Section I, Toxicology Branch I - IRS (H7509C)

009614

DATA EVALUATION REPORT

Study Type: 84-2a, Gene Mutation

TOX Chem. No.: 661A

Accession Number: N/A

MRID No.: 00078620

Test Material: Glyphosate, technical; Sample No. 4

Synonym: Roundup

Study Number: LF-78-161

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: Environmental Health Laboratory  
St. Louis, MO

Title of Report: Final Report on Salmonella Mutagenicity Assay of  
Glyphosate.

Authors: L. Flowers and L.D. Kier

Report Issued: June 16, 1978

Conclusions:

Glyphosate was negative for mutagenicity when tested up to 1000 ug/plate (or toxicity), both with and without S-9, in Salmonella typhimurium strains (TA98, TA100, TA1535, and TA1537). Positive controls run concurrently produced the expected positive mutagenic results.

Classification: Acceptable

Special Review Criteria (40 CFR 154.7): N/A

Note: Dr. Irving Mauer, geneticist, screened this study for acceptability.

00007

009614

Methods:

Standard methods were employed.

Review:

The following compounds and amounts were used as positive controls:

| Strain | S-9 Mix | Compounds                         | Amount/Plate |
|--------|---------|-----------------------------------|--------------|
| TA98   | -       | 4-nitroquinoline-N-oxide          | 0.1 mcg      |
| TA98   | +       | 2-acetamidofluorene               | 30 mcg       |
| TA100  | -       | 4-nitroquinoline-N-oxide          | 0.5 mcg      |
| TA100  | +       | benzo(a)pyrene                    | 2 mcg        |
| TA1535 | -       | NaNO <sub>2</sub>                 | 10 mg        |
| TA1535 | +       | tris(2,3-dibromopropyl)-phosphate | 30 mcg       |
| TA1537 | -       | 9-aminoacridine                   | 30 mcg       |
| TA1537 | +       | 2-aminoanthracene                 | 30 mcg       |

Results:Reverse Mutation (Gene Mutation) Assay1. TA98 and TA100

S-9 Ref: Litton IRL-148  
Solvent H<sub>2</sub>O

| <u>Without Microsomal Activation</u> |     |      | <u>Revertants per Plate</u> |       |      |        |        |
|--------------------------------------|-----|------|-----------------------------|-------|------|--------|--------|
| Amount per Plate                     |     | TA98 |                             | TA100 |      | TA1535 | TA1537 |
| 0.1 $\mu$ g                          | 31  | 28   | 24                          | 151   | 164  | 166    |        |
| 1.0 $\mu$ g                          | 19  | 21   | 15                          | 123   | 147  | 142    |        |
| 10 $\mu$ g                           | 15  | 21   | 21                          | 130   | 114  | 104    |        |
| 30 $\mu$ g                           | 21  | 20   | 18                          | 133   | 139  | 108    |        |
| 100 $\mu$ g                          | 21  | 27   | 15                          | 146   | 108  | 115    |        |
| 1000 $\mu$ g                         | TOX | TOX  | TOX                         | 77    | 92   | 77     |        |
| Solvent Controls                     | 26  | 28   | 18                          | 104   | 108  | 130    |        |
| Negative Control (H <sub>2</sub> O)  | 25  | 25   | 9                           | 102   | 103  | 93     |        |
| Positive Controls                    |     | 380  |                             |       | 1399 |        |        |

00038

G09614

S-9 Ref: Litton IRL-148  
Solvent H<sub>2</sub>O (Cont'd)

With Microsomal Activation

| Amount per Plate                    | TA98 |     |     | Revertants per Plate |     |     | TA1535 |  | TA1537 |  |  |
|-------------------------------------|------|-----|-----|----------------------|-----|-----|--------|--|--------|--|--|
|                                     |      |     |     | TA100                |     |     |        |  |        |  |  |
| 0.1 ug                              | 56   | 73  | 56  | 143                  | 104 | 127 |        |  |        |  |  |
| 1.0 ug                              | 52   | 50  | 65  | 152                  | 145 | 108 |        |  |        |  |  |
| 10 ug                               | 72   | 53  | 64  | 92                   | 133 | 135 |        |  |        |  |  |
| 30 ug                               | 78   | 76  | 40  | 111                  | 132 | 115 |        |  |        |  |  |
| 100 ug                              | 64   | 56  | 68  | 145                  | 125 | 138 |        |  |        |  |  |
| 1000 ug                             | TOX  | TOX | TOX | 104                  | 110 | 108 |        |  |        |  |  |
| Solvent Controls                    | 54   | 55  | 63  | 103                  | 98  | 108 |        |  |        |  |  |
| Negative Control (H <sub>2</sub> O) | 60   | 42  | 40  | 126                  | 116 | 114 |        |  |        |  |  |
| Positive Controls                   | 1234 |     |     | 369                  |     |     |        |  |        |  |  |

2. TA1535 and TA1537

S-9 Ref: Litton IRL-48  
Solvent H<sub>2</sub>O

Without Microsomal Activation

| Amount per Plate                    | TA98 |    |    | Revertants per Plate |     |     | TA1535 |     |     | TA1537 |     |     |
|-------------------------------------|------|----|----|----------------------|-----|-----|--------|-----|-----|--------|-----|-----|
|                                     |      |    |    | TA100                |     |     |        |     |     |        |     |     |
| 0.4 ug                              | 16   | 14 | 14 | 125                  | 95  | 85  | 3      | 2   | 3   | 4      | 0   | 3   |
| 2.0 ug                              | 9    | 9  | 16 | 98                   | 86  | 34  | 1      | 2   | 3   | 7      | 2   | 4   |
| 10 ug                               |      |    |    |                      |     |     | 4      | 1   | 1   | 7      | 2   | 4   |
| 30 ug                               |      |    |    |                      |     |     | 2      | 1   | 1   | 6      | 2   | 4   |
| 100 ug                              |      |    |    |                      |     |     | 1      | 2   | 2   | 48     | 5   | 7   |
| 1000 ug                             |      |    |    |                      |     |     | TOX    | TOX | TOX | TOX    | TOX | TOX |
| Solvent Controls                    | 20   | 13 | 6  | 110                  | 117 | 109 | 5      | 2   | 1   | 2      | 6   | 4   |
| Negative Control (H <sub>2</sub> O) | 4    | 14 | 9  | 66                   | 81  | 100 | 4      | 2   | 3   | 2      | 2   | 2   |
| Positive Controls                   |      |    |    |                      | 563 |     |        | 48  |     |        | 19  |     |

With Microsomal Activation

| Amount per Plate                    | TA98 |    |    | Revertants per Plate |     |     | TA1535 |     |     | TA1537 |     |     |
|-------------------------------------|------|----|----|----------------------|-----|-----|--------|-----|-----|--------|-----|-----|
|                                     |      |    |    | TA100                |     |     |        |     |     |        |     |     |
| 0.4 ug                              | 58   | 29 | 60 | 100                  | 122 | 111 | 6      | 13  | 7   | 15     | 22  | 33  |
| 2.0 ug                              | 40   | 52 | 54 | 108                  | 137 | 135 | 9      | 7   | 3   | 26     | 5   | 11  |
| 10 ug                               |      |    |    |                      |     |     | 9      | 5   | 8   | 37     | 9   | 16  |
| 30 ug                               |      |    |    |                      |     |     | 8      | 6   | 5   | 27     | 10  | 26  |
| 100 ug                              |      |    |    |                      |     |     | 6      | 3   | 6   | 13     | 10  | 37  |
| 1000 ug                             |      |    |    |                      |     |     | TOX    | TOX | TOX | TOX    | TOX | TOX |
| Solvent Controls                    | 54   | 48 | 45 | 135                  | 137 | 121 | 16     | 9   | 5   | 12     | 45  | 27  |
| Negative Control (H <sub>2</sub> O) | 43   | 44 | 44 | 95                   | 86  | 98  | 8      | 13  | 9   | 11     | 19  | 12  |
| Positive Controls                   | 1457 |    |    | 641                  |     |     |        | 198 |     |        | 95  |     |

G00039

009614

62819:I:Dykstra:LHED-07:LRAFT:KEVRIC:04/23/91:05/18/91:aw:wo:aw  
R:62897:Dykstra:LHED-07:KEVRIC:05/01/91:06/01/91:DD

00030

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/11/91*  
Section I, Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardiner, Section Head *Roger Gardiner 5/14/91*  
Section I, Toxicology Branch I - IRS (H7509C)

009614

DATA EVALUATION REPORT

Study Type: 84-2(b) - Structural TOX Chem. No.: 661A  
Chromosomal Aberrations:  
Mouse Dominant Lethal Assay

Accession Number: N/A HRID No.: 00046364

Test Material: Glyphosate, technical; 98.7% purity;  
Lot No. XHJ-64

Synonyms: Roundup

Study Nos.: IRDC No. 401-064; Monsanto No. IR-79-014

Sponsor: Monsanto Company  
St. Louis, MO

Testing Facility: IRDC  
Mattawan, MI

Title of Report: Dominant Lethal Study in Mice.

Author: Dean E. Rodwell

Report Issued: April 16, 1980

Conclusions:

Glyphosate was negative for a dominant lethal mutation in mice at dosages up to 2000 mg/kg, given as a single oral dose. All standard criteria were met except that there was no evidence of clinical or reproductive toxicity (hence, no evidence that glyphosate reached testes), and there were insufficient numbers of matings (fewer than 20 per week) for statistical constraints. Normally 30 to 50 pregnancies per week/dose are needed for statistical analysis.

Classification: Unacceptable

Special Review Criteria (40 CFR 154.7): N/A

Note: Dr. Irving Mauer, geneticist, screened the mutagenicity study for acceptability.

00001

009614

Review:

Quality assurance was signed by Barry W. Benson and dated March 18, 1980.

Test Materials - glyphosate technical; 98.7% purity; Lot No. XIII-64. Positive control: Cytosan (cyclophosphamide), 240 mg/kg. Negative control: 0.5% methocel.

Animals - 90-day-old male CD-1 mice, obtained from Charles River Breeding Laboratories, Portage, MI, were used in the study. Eight hundred sexually mature, untreated virgin female mice of the same source and strain were used. The mice were individually housed, except during mating, and maintained in a controlled environment. The mice received Purina Rodent Chow #5002 and tap water ad libitum.

Methods:

Randomized groups of 10 male mice were divided into five groups. The groups received the following (I): Negative control; (II): Positive control (240 mg/kg); (III): Glyphosate, 200 mg/kg; (IV): Glyphosate, 800 mg/kg; (V): Glyphosate, 2000 mg/kg. The male mice were orally dosed on only the first day of the study at a 10 mL/kg volume, except for the positive control group, which was by intraperitoneal injection. Female mice received no treatment.

Immediately following treatment, each male was cohabitated with two virgin females for 7 consecutive days. Following the 7-day period, two new females were cohabitated with each male and the original females were returned to their individual cages. Females continued to be replaced in this manner for 3 weeks so that each male was mated with a total of 16 females.

Mice were observed daily for toxicity and mortality. Clinical observations and body weight were measured weekly for 9 weeks.

Thirteen days after mid-week of their caging and presumptive mating, each female was sacrificed and the uterus and ovaries were exposed by an abdominal incision. The number and location of viable and nonviable fetuses, early and late resorptions, total implantations and corpora lutea per dam were recorded. Gross necropsy examinations of thoracic and abdominal cavities and organs of the dams were performed.

Statistics:

Fetal deaths per dam and postimplantation loss were compared by the Mann-Whitney U-test as described by Siegel and Weil to judge significance of differences. The number of dams with fetal

00002

009614

deaths was compared using the Chi-square test criterion with Yate's correction for 2 x 2 contingency tables and/or Fisher's exact probability test as described by Siegel to judge significance of difference. The mean number of live fetuses and corpora lutea were compared by analysis of variance (one-way classification), Bartlett's test for homogeneity of variances, and the appropriate t-test (for equal or unequal variances) as described by Steel and Torrie using Dunnett's multiple comparison tables to judge significance of differences.

#### Results:

There were no treatment-related toxic signs in the glyphosate groups. In the positive control group, yellow staining of the anogenital region was observed in 4 out of 10 males during various weeks of the study.

There were four unscheduled deaths: one male at 2000 mg/kg during week 6; one mated female at 2000 mg/kg during week 2; one female at 800 mg/kg at week 5; and one female at 200 mg/kg at week 3. The cause of death could not be determined.

There were no compound-related effects in body weight of male glyphosate-treated mice and positive control mice in comparison to the untreated negative control.

The principal criterion for determining a dominant lethal mutagenic effect is the increase in the number of early fetal deaths in treated groups in comparison to negative controls.

Cytosan displayed a dominant lethal effect, as evidenced by an increase in the proportion of early fetal deaths in this group, when compared to the negative control during the first three weeks of mating. Glyphosate-treated males did not show a mutagenic effect by this criterion up to 2000 mg/kg over the entire 8-week mating cycle.

The following tables, as presented in the report, show these results.

00003



# Summary of Group Mean Maternal Observations at Parturition

| Dosage Level | Fetuses |           |        |    |           |    | Resorptions |    |       |    |             |    | Postimplan-   |    | Total  |    | Corpora |  |
|--------------|---------|-----------|--------|----|-----------|----|-------------|----|-------|----|-------------|----|---------------|----|--------|----|---------|--|
|              | Number  |           | Viable |    | Nonviable |    | Late        |    | Early |    | tation Loss |    | Implantations |    | Luteal |    |         |  |
|              | Gravid  | Nongravid | Mean   | SD | Mean      | SD | Mean        | SD | Mean  | SD | Mean        | SD | Mean          | SD | Mean   | SD |         |  |

## Mating Week 1

|                                  |    |   |       |      |     |      |     |      |       |      |       |      |      |      |      |      |
|----------------------------------|----|---|-------|------|-----|------|-----|------|-------|------|-------|------|------|------|------|------|
| 0 mg/kg<br>(Vehicle Control):    | 17 | 3 | 11.8  | 1.08 | 0.0 | 0.00 | 0.0 | 0.00 | 0.4   | 0.93 | 0.6   | 0.93 | 12.5 | 1.28 | 12.9 | 1.68 |
| 240 mg/kg<br>(Positive Control): | 15 | 5 | 4.1** | 3.77 | 0.0 | 0.00 | 0.1 | 0.35 | 4.9** | 2.12 | 5.1** | 2.12 | 9.1  | 2.95 | 11.3 | 2.80 |
| 200 mg/kg:                       | 15 | 5 | 10.5  | 3.58 | 0.0 | 0.00 | 0.1 | 0.35 | 0.7   | 1.54 | 0.8   | 1.52 | 11.3 | 2.74 | 10.1 | 2.27 |
| 800 mg/kg:                       | 16 | 4 | 10.5* | 1.83 | 0.0 | 0.00 | 0.3 | 0.70 | 0.8   | 1.11 | 1.1   | 3.20 | 11.6 | 1.78 | 11.8 | 1.68 |
| 2000 mg/kg:                      | 17 | 3 | 11.6  | 2.32 | 0.0 | 0.00 | 0.1 | 0.31 | 0.4   | 0.62 | 0.5   | 0.72 | 12.2 | 2.43 | 13.2 | 2.17 |

## Mating Week 2

|                                  |    |   |       |      |     |      |     |      |       |      |       |      |      |      |       |      |
|----------------------------------|----|---|-------|------|-----|------|-----|------|-------|------|-------|------|------|------|-------|------|
| 0 mg/kg<br>(Vehicle Control):    | 17 | 3 | 11.1  | 3.35 | 0.0 | 0.00 | 0.2 | 0.53 | 0.9   | 2.03 | 1.1   | 2.05 | 12.2 | 2.30 | 13.2  | 2.70 |
| 240 mg/kg<br>(Positive Control): | 16 | 4 | 3.3** | 3.34 | 0.0 | 0.00 | 0.0 | 0.00 | 4.1** | 1.89 | 4.1** | 1.89 | 7.4  | 3.18 | 9.1** | 0.44 |
| 200 mg/kg:                       | 16 | 4 | 11.4  | 2.31 | 0.0 | 0.00 | 0.1 | 0.25 | 1.0   | 1.41 | 1.1   | 1.39 | 12.5 | 1.90 | 10.4  | 1.55 |
| 800 mg/kg:                       | 18 | 2 | 10.1  | 3.26 | 0.0 | 0.00 | 0.8 | 2.81 | 0.7   | 1.46 | 1.5   | 3.22 | 11.6 | 1.89 | 10.1  | 2.49 |
| 2000 mg/kg:                      | 18 | 2 | 12.1  | 1.89 | 0.0 | 0.00 | 0.2 | 0.44 | 0.8   | 0.90 | 1.0   | 1.06 | 13.1 | 1.25 | 10.4  | 1.42 |

## Mating Week 3

|                                  |    |   |       |      |     |      |     |      |       |      |       |      |      |      |        |      |
|----------------------------------|----|---|-------|------|-----|------|-----|------|-------|------|-------|------|------|------|--------|------|
| 0 mg/kg<br>(Vehicle Control):    | 14 | 6 | 12.0  | 1.33 | 0.0 | 0.00 | 0.1 | 0.27 | 0.5   | 0.75 | 0.6   | 0.76 | 12.6 | 1.22 | 10.0   | 1.38 |
| 240 mg/kg<br>(Positive Control): | 16 | 4 | 4.8** | 3.1* | 0.0 | 0.00 | 0.6 | 2.00 | 4.4** | 0.18 | 4.9** | 3.34 | 9.8  | 2.77 | 10.9** | 2.25 |
| 200 mg/kg:                       | 18 | 2 | 12.0  | 2.42 | 0.0 | 0.00 | 0.1 | 0.24 | 1.3   | 1.50 | 1.4   | 1.50 | 13.4 | 1.46 | 14.4   | 2.67 |
| 800 mg/kg:                       | 18 | 2 | 11.4  | 2.15 | 0.0 | 0.00 | 0.1 | 0.24 | 0.8   | 1.00 | 0.8   | 0.99 | 12.2 | 1.83 | 77.1   | 1.77 |
| 2000 mg/kg:                      | 17 | 3 | 10.3* | 2.95 | 0.0 | 0.00 | 0.8 | 3.15 | 0.6   | 0.80 | 1.4   | 3.10 | 11.4 | 1.17 | 12.0   | 1.16 |

## Mating Week 4

|                                  |    |   |      |      |     |      |     |      |     |      |     |      |      |      |      |      |
|----------------------------------|----|---|------|------|-----|------|-----|------|-----|------|-----|------|------|------|------|------|
| 0 mg/kg<br>(Vehicle Control):    | 19 | 1 | 10.4 | 3.76 | 0.0 | 0.00 | 0.9 | 3.21 | 0.8 | 1.27 | 1.7 | 3.35 | 12.1 | 2.31 | 12.5 | 2.41 |
| 240 mg/kg<br>(Positive Control): | 13 | 7 | 10.9 | 2.87 | 0.0 | 0.00 | 0.2 | 0.61 | 1.5 | 2.07 | 1.8 | 2.42 | 12.7 | 1.44 | 13.5 | 1.05 |
| 200 mg/kg:                       | 17 | 3 | 10.8 | 3.26 | 0.0 | 0.00 | 0.2 | 0.39 | 0.6 | 1.00 | 0.8 | 1.03 | 11.4 | 2.90 | 11.9 | 2.95 |
| 800 mg/kg:                       | 17 | 3 | 11.3 | 3.10 | 0.0 | 0.00 | 0.0 | 0.00 | 1.2 | 1.67 | 1.2 | 1.67 | 12.5 | 2.48 | 11.2 | 2.35 |
| 2000 mg/kg:                      | 14 | 6 | 9.9  | 4.44 | 0.0 | 0.00 | 0.0 | 0.00 | 0.9 | 0.86 | 0.9 | 0.86 | 10.8 | 3.83 | 12.0 | 4.28 |

SD = Standard Deviation

\*Significantly different from control group  $p < 0.05$ .

\*\*Significantly different from control group  $p < 0.01$ .

009614

000394

009614

## Parting Week 5

## Motivation Week 6

Matting Week 7

### Matiny Week n

Values from the trended groups specified to be tested in the report did not differ significantly from the control group.

SD = Standard Deviation

00035

009614

Discussion:

The authors concluded that glyphosate has no clastogenic effect on bone marrow cells under the conditions of the assay. Statistical analysis supported their results; however, there was a slight but nonsignificant increase in achromatic gaps (not considered aberrations) in the glyphosate treated group. Our assessment is that the authors' data support the conclusions. The assay sensitivity was supported by appropriate response from the positive control relative to the solvent control. The highest dose level of glyphosate used was limited to the test compound's solubility and by the volume that could be injected into a rat. A range-finding study (Study No. 830082) used to set the maximum dose presented data on cytotoxicity for levels of test compound up to 1000 mg/kg. However, there was no concurrent cytotoxicity data. Moreover, only a single concentration of test compound was tested.

Conclusions:

Glyphosate did not induce significant clastogenic effects in rats under conditions of the study which was limited to the assay of a single dose level of 1000 mg/kg. Cylophosphamide at 25 mg/kg caused a highly significant number of chromosomal aberrations demonstrating the sensitivity of the assay. Under the conditions of the study, glyphosate did not cause any fatalities or other signs of toxicity. Monsanto has addressed these issues in the letter of November 26, 1984 (memorandum of W. Dykstra of March 12, 1985, attached).

Classification: Acceptable

00009

009614

U.S. E.P.A.

REGISTRATION DIVISION

SUBJECT: Glyphosate; EPA Reg. # 44-384; Registrant's response to review of mutagenicity study  
Case # 661A

TO: Robert Taylor  
Product Manager (25)  
Registration Division (TS-767)

THRU: Robert P. Zendzian, Ph.D.  
Acting Head, Review Section IV  
Toxicology Branch  
Hazard Evaluation Division (TS-769)

FROM: William Dykstra, Ph.D. *William Dykstra*  
Toxicology Branch  
Hazard Evaluation Division (TS-769) *3/12/85*

Recommendations:

1. The letter from Monsanto dated November 26, 1984 adequately addresses the Toxicology Branch review. The Toxicology Branch review of the *in vivo* bone marrow cytogenetics study of glyphosate in Sprague-Dawley rats stated that the study was unacceptable since dose-response data were not available (only a single dose) and concurrent cytotoxicity data were not available. The study number was ML-83-236.

Monsanto states in their letter that the range finding study was conducted at 200-1000 mg/kg. No cytotoxicity was produced in the range-finding study and, therefore, the single dose level of 1000 mg/kg was used.

Therefore, the study is acceptable since the previous basis of evaluation has been adequately addressed.

Review:

1. No new toxicity data were submitted.
2. A copy of the previous review is attached.

Attachment

181

00100

BEST AVAILABLE COPY

CONFIDENTIAL BUSINESS INFORMATION  
DOES NOT CONTAIN  
NATIONAL SECURITY INFORMATION (EO 12065)

009614

EPA: 68-01-6567  
TASK: 67  
June 4, 1984

Case file No. 6-614

DATA EVALUATION RECORD

GLYPHOSATE

Mutagenicity (Range-Finding Study)

CITATION: U.S. A.P. Effects of glyphosate on rat bone marrow cells. An unpublished report (study no. ML-83-160) prepared for Monsanto Agricultural Products Company by Environmental Health Laboratory, Monsanto Co. St. Louis, MO. Dated October 21, 1983.

REVIEWED BY:

William McLellan, Ph.D.  
Senior Scientist  
Dynamac Corporation

Signature: William L. McLellan  
Date: 6 June 1984

I. Cecil Felkner, Ph.D.  
Mgr. Genetic Toxicology Dept.  
Dynamac Corporation

Signature: Ira Cecil Felkner  
Date: 6-6-84

Cipriano Cueto, Ph.D.  
Department Director  
Dynamac Corporation

Signature: Cipriano Cueto  
Date: 6-6-84

APPROVED BY:

William Dykstra, Ph.D.  
EPA Scientist

Signature: William Dykstra  
Date: 6-11-84

009614

DATA EVALUATION RECORD

STUDY TYPE: Mutagenicity (range-finding study).

CITATION: Li, A.P. Effects of glyphosate on rat bone marrow cells. An unpublished report (study no. ML-83-160) prepared for Monsanto Agricultural Products Company by Environmental Health Laboratory, Monsanto Co. St. Louis, MO. Dated October 21, 1983.

ACCESSION NUMBER: 251737.

LABORATORY: Environmental Health Laboratory, Monsanto Co. St. Louis, MO.

QUALITY ASSURANCE STATEMENT: Present, signed and dated October 21, 1984.

TEST MATERIAL: The test material was identified as glyphosate (EHL sample No. T630044) a white powder having a purity of 98.7 percent.

MATERIAL AND METHODS:

Preparation of Test Material: A stock solution of 100 mg/ml was prepared by suspending glyphosate in Hank's balanced salt solution (HBBS) and adjusting the pH to 7.5 with sodium hydroxide. Dilutions of the stock solution in HBBS were freshly prepared to yield solutions of 20, 40, 60, and 80 mg/ml.

Controls: Hank's buffered salt solution 10 ml/kg was used as the vehicle control.

Animals: The animals used in the study were male and female Sprague-Dawley rats [CD(SD)BR] from Charles River Breeding Laboratories. The animals were approximately 10 weeks old at the time of test material administration; the males weighed 264-299 g and females weighed 179-202 g. Water and Purina Laboratory Chow were provided ad libitum except for a 14-24 hours fasting period just prior to dosing. Animals were maintained in individual cages in rooms maintained at 70-74 ° F and a relative humidity of between 25 and 60 percent. The rooms had 12-hour light/dark cycles.

Experimental Design: Rats (4/sex/group) were fasted overnight and then injected intraperitoneally with 10 ml of HBSS containing glyphosate. The final doses in the groups were 0, 200, 400, 600, 800, and 1,000 mg/kg. Four hours after administration of glyphosate or vehicle control, 4 mg/kg colchicine were administered ip, and two hours later the animals were sacrificed by CO<sub>2</sub> asphyxiation and by severance of their spinal cords.

009614

Preparation of Bone Marrow Cells: Bone marrow was separated from each femur into a 5 ml plastic syringe containing 2 ml HBSS. The contents were added to plastic centrifuge tubes containing 5 ml HBSS and incubated at 37° C until they were prepared for analysis.

Cell Viability Determination: An aliquot of the cell suspension was stained with acridine orange and ethidium bromide (EPL SCP L-58081-0004). Slides were prepared, and approximately 100 cells/animal at each dose level were examined by fluorescent microscopy. Since viable cells take up acridine orange and appear green and non-viable cells take up ethidium bromide and appear orange, the viable cells could be quantitated.

Determination of Mitotic Index: The cell suspensions were centrifuged, the pellet suspended in 1 ml 0.075 M KCl at 37° C, and an additional 5 ml of KCl added. After 30 min incubation at 37° C, 1 ml Corney's fixative was added (methanol-glacial acetic acid 3/1, v/v). The cells were then pelleted, 5 ml of fresh fixative added, and the cell suspension stored at 4° C. One to 2 drops of cell suspensions were fixed on slides and stained 15-20 min with 2 percent Geimsa solution. The slides were then rinsed and air dried.

Approximately 500 cells/slide were counted to quantitate metaphase and non-metaphase cells. The mitotic index (ratio of mitotic cells to the total number of cells counted) was calculated from this data.

#### RESULTS:

Viability: Viability ranged from 95.8 to 98.5 percent in males and from 93.2 to 97.8 percent in females groups. Solvent control values were 96.8 percent for males and 98.5 percent for females. Hence, the author assessed that glyphosate at doses up to 1000 mg/kg, had no effect on cell viability.

Mitotic Index: The mitotic index for control males was 0.028 and for control females 0.032 (average of 4 animals). The mitotic index for males dosed at 800 mg/kg was slightly but significantly ( $p = 0.05$ ) increased over controls (0.045). In other dose groups of males the mitotic indices were similar to controls (0.030-0.037).

In glyphosate-treated females the mitotic index was slightly lower at 400 mg/kg (0.019,  $p = 0.036$ ) than in controls, but there were no significant differences at other dose levels (mitotic indices ranged from 0.024-0.039).

#### DISCUSSION:

The authors concluded that doses up to 1,000 mg/kg glyphosate could be used to score the potential cytogenetic effect in vivo in rats since there was no significant reduction in the mitotic index. However, it was noted

009614

that the highest dose used in the range finding study was the maximum dose that could be effectively administered based on solubility of the test compound and the volume that could be injected ip into rats.

This reviewer agrees the conclusions. The 4 percent reduction in mitotic index in 400 mg/kg females may not be compound related, since there was no dose-response relationship. Furthermore, such a slight lowering of the mitotic index would not affect the cytogenetic study. In selecting doses for in vivo cytogenicity testing, the limit should be based on solubility; the maximum dose will be inadequate if cytotoxic responses are the basis for selecting the maximum dose.

CONCLUSIONS:

Glyphosate (at dose levels between 200 - 1,000 mg/kg) did not cause any loss of viability in vivo in rat marrow cells. There was a slight decrease (4 percent) in mitotic index in females at 400 mg/kg but not at higher doses, and no effects in males. Therefore 1,000 mg/kg can be tolerated in an in vivo cytogenicity assay in rats.

CLASSIFICATION: Acceptable.

00104

BEST AVAILABLE COPY



Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/1/91*  
Toxicology Branch I - IRS (H7509C)  
*for* Secondary Reviewer: Roger Gardner, Section Head *Home to Mr. Shuley 5/1/91*  
Toxicology Branch I - IRS (H7509C) **009614**

**DATA EVALUATION REPORT**

Study Type: 84-4; Other Genotoxic Effects TOX Chem. No.: 661A

Accession No.: 251737 MRID No.: 00132686

Test Material: Glyphosate Technical, Lot No. XHJ-64, Purity 98.7%

Synonyms: Compound JJN-1020

Study Number: AH-83-181

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: Naylor Dana Institute, Valhalla, NY 10595

Title of Report: The Hepatocyte Primary Culture/DNA Repair Assay on Compound JJN-1020 Using Rat Hepatocytes in Culture.

Authors: G.M. Williams and C. Tong

Report Issued: October 21, 1983

Conclusions:

Under the conditions of the assay, glyphosate did not induce DNA damage at concentrations between  $1.25 \times 10^{-5}$  and  $1.25 \times 10^{-1}$  mg/mL. All relevant study criteria were met except the following:

1. No preliminary toxicity testing reported,
2. No criteria for dose-selection, and
3. Stated to have been tested up to solubility limit, but no data or documentation presented.

Classification: Unacceptable

Special Review Criteria (40 CFR 154.7):

Note: Dr. Irving Mauer, geneticist, screened this mutagenicity study for acceptability. The DER is based on parts of a Dynamac review.

009614

Review:

Quality Assurance Statement - Although the report stated that a quality assurance review was prepared for the study, a signed and dated report was not present.

Test Material - The test material was identified as JJW-1020 of Lot No. XHJ-64, provided by Monsanto Company. Its purity was 98.7 percent and it was reported to be soluble in 0.1 N NaOH.

Materials and Methods:

Hepatocyte Primary Cultures (HPC) - The cells used in the study were freshly prepared hepatocytes from adult male F-344 rats. The hepatocytes were obtained by a modification of the procedure developed by Williams et al.\* The rats were anesthetized with 50 mg/kg sodium nembutal and perfused with sterilized Solutions I and II by means of a sterile peristaltic pump. Solution I contained 0.5 mM ethyleneglycol-bis(B-aminoethyl ether) N-N'-tetracetic acid (EGTA) in calcium and magnesium-free Hank's balanced salt solution, buffered with 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes) adjusted to pH 7.35, using 1N NaOH. Solution II contained 100 unit/mL of type I collagenase in Williams' medium E (WME) buffered by 10 mM Hepes (pH 7.35).

Perfusion was through the portal vein via a 21 gauge butterfly needle using a flow rate of 8 mL/min at 37 °C for Solution I. At the start of perfusion with Solution I, the process of ligating the infrahepatic vena cava was completed and the vein severed distally so that the perfusate ran to the waste container. When the liver was uniformly balanced, a cannula was inserted into the thoracic inferior vena cava so that the perfusate could be collected by means of this return cannula; then the flow rate was increased to 40 mL/min for 2.5 minutes. The perfusion with Solution I was followed by perfusion with sterile Solution II at a flow rate of 20 mL/min at 37 °C for 10 minutes (not recirculating the return perfusate). The liver was covered with sterile gauze warmed by a 40W light bulb.

The perfused liver was removed, trimmed of extraneous fat and connective tissue into a Petri dish with warm WME under sterile conditions. The tissue was then transferred to fresh Solution II. After opening the liver at numerous points on the inferior surface and removal of the capsule, the cells were detached by "gentle combing with a stainless steel comb and shaking off loose cells." After complete combing, the fibrous

---

\*Williams, G.M., Bermutes, E., and Scaramuzzino, D. (1977) Vitro 13:809-817.

00106

009614

plug was discarded and 25 mL aliquots of the hepatocyte suspension were pipetted into 50 mL centrifuge tubes, adjusting the volume to 50 mL with WME, supplemented with 10 percent calf serum and 50  $\mu$ g/mL gentamycin (WMES). The cell suspension was centrifuged for 2.5 minutes at 50 x g, and the cell pellet was resuspended in WMES. A 20-fold dilution of the cell suspension was prepared and 0.5 mL of this diluted suspension was added to 0.1 mL of 0.4 percent trypan blue so that viability (differential staining) could be assessed using a hemocytometer. The author stated that cell yields of approximately  $2.0 \times 10^8$  per 100 g body weight and hepatocytes viabilities of about 90 percent were usually obtained.

For the HPC/DNA studies,  $5 \times 10^5$  cell/mL WMES were seeded immediately onto 25 mm round coverslips in 25 mm 6 well dishes under 5 percent  $\text{CO}_2$ , humidified in an incubator at 37 °C. The coverslips were washed with 1 mL WME 2 hours after seeding so that only the attached viable cells remained.

Preparation of Test Material - The test material, JJN-1020, was solubilized in 0.1 N NaOH at a maximum solubility of 12.5 mg/mL. Serial dilutions of the stock solution were made in 0.1 N NaOH and 20  $\mu$ L of the stock solutions were added to 2 mL of assay medium so that the final test concentrations were  $1.25 \times 10^{-1}$ ,  $6.25 \times 10^{-2}$ ,  $1.25 \times 10^{-2}$ ,  $6.25 \times 10^{-3}$ ,  $1.25 \times 10^{-4}$  and  $1.25 \times 10^{-5}$  mg/mL.

Controls - The positive control chemical was benzo(a)pyrene at a final concentration of  $5 \times 10^{-5}$  M and the negative control was pyrene also at  $5 \times 10^{-5}$  M. Solvent controls included 1 percent dimethylsulfoxide (DMSO) and 1 percent of 0.1 N NaOH. An untreated negative control was also used.

Hepatocyte Primary Culture DNA Repair Assay - The HPC/DNA repair assay was performed using methods developed by Williams<sup>1,2</sup>. Immediately after washing with 1 mL WME, the test material and 20  $\mu$ Ci/mL tritiated thymidine ( $[^3\text{H}]\text{-TdR}$ ) at 60 to 80 Ci/mM were added to 2 mL of the WME cell suspension. The test material was applied at five logarithmically decreasing concentrations on triplicate coverslips with the appropriate parallel positive and negative (untreated and solvent) controls.

After incubation for 18 to 24 hours in the presence of test material in  $[^3\text{H}]\text{-TdR}$ -WME, coverslips were removed from the wells and successively rinsed three times with 100 mL of WME. Each coverslip was then immersed for 10 minutes, cell surface up in 2

<sup>1</sup>Williams, G.M. (1977) Cancer Res. 37:1845-1851.

<sup>2</sup>Williams, G.M. (1980) In: Chemical Mutagens. Vol VI eds. de Serres, F.J. and Hollaender, A. Plenum Press, NY pages 61-79.

00107

009614

mL of 1 percent sodium citrate, in clean 6-well dishes, to cause nuclear swelling (permits better nuclear grain quantification), and finally fixed by three 30-minute changes of glacial acetic acid (3:1), air dried, and mounted on glass slides. Slides were dipped into NTA emulsion (Eastman Kodak) that had been prewarmed at 45 °C for 1 hour, removed, and dried in a light-tight box. Slides were wrapped in foil and stored at 4 °C in cardboard slide boxes.

Ten days after storage, autoradiographs were developed for 4 minutes in D19 (Eastman Kodak), placed in acidified tap water for 30 seconds, immersed in fixer (Eastman Kodak) for 10 minutes, and washed with tap water for 5 minutes. Next, slides were stained with Harris' alum hematoxylin, counterstained with eosin, dehydrated through 100 percent ethanol, air dried, and the coverslips sealed with Permount.

Slide Evaluation - Nuclear grains were scored with an Artek Model 880 electric counter equipped with a microscopic attachment, using the area mode (permits distinction between discrete grains, even in aggregates). The net increase in grains induced by the test chemical or the positive control relative to the solvent control was the method used for quantification. To avoid artifacts, only cells with swollen nuclei (viable cells at fixation) and those evenly coated with emulsion were scored. From each coverslip quadrant, between 5 and 20 randomly selected cells were scored (depending upon the nuclear/cytoplasmic grain ratio\*). Background grain counts were assessed by counting three nuclear sized areas adjacent to the nucleus, and the net nuclear grain counts were calculated by subtracting the highest cytoplasmic count from the nuclear count.

Data Interpretation - By subtracting counts of the highest cytoplasmic background, false positive scores could be avoided. A minimum net grain count of five per nucleus, consistently observed in triplicate coverslips was the criteria for a positive sample, and if the minimum was consistently observed throughout the experiment, the compound was considered positive.

If S phase cells, identified by morphology and/or high grain density in the autoradiograph, were absent, then a cytotoxic response had occurred. A negative result was reported if less than five net nuclear grains counts were observed at the highest noncytotoxic dose.

---

\*Rogers, A.W. (1973) In: Techniques of Autoradiography. Elsevier Sci. Pub. Co., p. 218.

009614

**Results:**

The authors reported that cytotoxicity was not observed when the HPC cells were exposed to the highest concentrations of JJN-1020 used and that none of the net grain counts/nucleus exceeded a value of 5. The highest net grain value for the test material was  $1.4 \pm 0.5$  ( $1.25 \times 10^{-1}$  mg JJN-1020 per mL) while the negative control values were  $0.3 \pm 0.5$ ,  $0.3 \pm 0.1$ ,  $0.2 \pm 0.3$ , and  $0.4 \pm 0.4$  for DMSO, 0.1N NaOH, untreated cell culture, and pyrene, respectively. The positive control, B(a)P, gave a net grain count of  $22.9 \pm 9.7$ . Hence, sensitivity of the assay was adequate.

**Discussion:**

The author concluded that under the conditions of the HPC/DNA repair assay, no genotoxicity was induced by treatment with JJN-1020 at concentrations from  $1.25 \times 10^{-5}$  to  $1.25 \times 10^{-1}$  mg/mL.

**Conclusions:**

Under the conditions of the assay and as reported, the test material (JJN-1020), glyphosate, did not induce DNA damage at concentrations between  $1.25 \times 10^{-5}$  and  $1.25 \times 10^{-1}$  mg/mL.

**Classifications: Unacceptable**

1. No preliminary toxicity testing,
2. No criteria for dose selection, and
3. Stated to have been tested up to solubility limit, but no data or documentation presented.

00109

Reviewed By: William Dykstra, Ph.D. *William Dykstra 5/31/91*  
Section I, Toxicology Branch I - IRS (H7509C)  
Secondary Reviewer: Roger Gardner, Section Head *Pamela M. Hurley 5/14/91*  
Section I, Toxicology Branch I - IRS (H7509C)

009614

DATA EVALUATION REPORT

Study Type: 84-4, Other Genotoxic Effects, TOX Chem. No.: 661A  
Rec-Assay in B. subtilis

Accession Number: N/A

MRID No.: 00078619

Test Material: Glyphosate, technical; 98.4% purity

Synonym: CP67573

Study Number: None

Sponsor: Monsanto Company, St. Louis, MO

Testing Facility: Institute of Environmental Toxicology, Japan

Title of Report: Microbial Mutagenicity Testing on CP67573  
(Glyphosate).

Authors: Y. Shirasu, M. Moriya, T. Ohta

Report Issued: July 20, 1978

Conclusions:

Glyphosate technical was negative for mutagenicity up to 2000 ug/disk in the rec-assay with Bacillus subtilis H17 (rec<sup>+</sup>) and H45 (rec<sup>-</sup>) and in the reverse mutation assays with and without S-9 up to 5000 ug/plates (or toxicity) employing Escherichia coli WP2 hcr and Salmonella typhimurium TA strains (TA1535, TA1537, TA1538, TA100, and TA98) as tester strains.

Classification: Acceptable

Special Review Criteria (40 CFR 154.7): N/A

Note: Dr. Irving Hauer, geneticist, screened these studies for acceptability.

00110

009614

Methods:

Standard methods were employed.

Results:

1. Rec-Assay - As shown in the Table below, glyphosate did not show any inhibitory zone in H17 and M45 at all the tested doses of 20 to 2000 ug/disk.

The positive control, Mitomycin C, caused an 11 mm difference in the length of the inhibitory zones of the two strains.

The negative control, Kanamycin, included similar lengths of inhibitory zones in the two strains.

Rec-Assay With B. subtilis M45 and H17

| Compound       | <u>ug/Disk</u> | Inhibition Zone (mm) |     | Difference (mm) |
|----------------|----------------|----------------------|-----|-----------------|
|                |                | M45                  | H17 |                 |
| Control (DMSO) |                | 0                    | 0   | 0               |
| CP67573        | 20             | 0                    | 0   | 0               |
|                | 100            | 0                    | 0   | 0               |
|                | 200            | 0                    | 0   | 0               |
|                | 500            | 0                    | 0   | 0               |
|                | 1000           | 0                    | 0   | 0               |
|                | 2000           | 0                    | 0   | 0               |
| Kanamycin      | 10             | 7                    | 5   | 2               |
| Mitomycin C    | 0.1            | 11                   | 0   | 11              |

2. Reverse Mutation Assay (gene mutation) - As shown in the Table below, glyphosate did not induce any significant increase in the numbers of revertant colonies of any strains over the control values, either in the presence or absence of S-9.

00111

009614

The positive controls, in contrast, induced reverse mutations in the tester strains.

Reverse Mutation Tests With and Without a Liver  
Metabolic Activation System

| Compound                      | ug/Plate | S-9<br>Mix | Revertant Colonies/Plate |        |       |        |        |      |
|-------------------------------|----------|------------|--------------------------|--------|-------|--------|--------|------|
|                               |          |            | WP2 hcr                  | TA1535 | TA100 | TA1537 | TA1538 | TA98 |
| Control<br>(H <sub>2</sub> O) |          | -          | 20                       | 6      | 167   | 9      | 10     | 24   |
|                               |          |            | 24                       | 14     | 129   | 10     | 13     | 23   |
| CP67573                       | 10       | -          | 22                       | 2      | 130   | 3      | 17     | 27   |
|                               |          |            | 21                       | 5      | 160   | 7      | 24     | 28   |
|                               | 50       | -          | 12                       | 5      | 151   | 5      | 15     | 33   |
|                               |          |            | 25                       | 5      | 159   | 6      | 15     | 40   |
|                               | 100      | -          | 18                       | 4      | 143   | 8      | 17     | 20   |
|                               |          |            | 20                       | 5      | 160   | 8      | 24     | 20   |
|                               | 500      | -          | 21                       | 3      | 118   | 11     | 7      | 31   |
|                               |          |            | 26                       | 1      | 143   | 9      | 15     | 24   |
|                               | 1000     | -          | 15                       | 9      | 87    | 10     | 18     | 21   |
|                               |          |            | 18                       | 12     | 120   | 10     | 12     | 23   |
|                               | 5000     | -          | *                        | 6      | 58    | 3      | 6      | 10   |
|                               |          |            | *                        | 6      | 87    | 3      | 7      | 3    |
| Control<br>(H <sub>2</sub> O) |          | +          | 17                       | 6      | 139   | 7      | 8      | 22   |
|                               |          |            | 22                       | 5      | 140   | 5      | 11     | 16   |
| CP67573                       | 10       | +          | 25                       | 4      | 110   | 3      | 16     | 19   |
|                               |          |            | 18                       | 1      | 135   | 3      | 11     | 23   |
|                               | 50       | +          | 27                       | 9      | 123   | 7      | 13     | 21   |
|                               |          |            | 22                       | 5      | 131   | 9      | 17     | 26   |
|                               | 100      | +          | 33                       | 5      | 125   | 11     | 18     | 9    |
|                               |          |            | 17                       | 7      | 115   | 6      | 14     | 20   |
|                               | 500      | +          | 23                       | 3      | 138   | 12     | 15     | 19   |
|                               |          |            | 30                       | 3      | 111   | 5      | 7      | 26   |
|                               | 1000     | +          | 29                       | 11     | 97    | 11     | 20     | 15   |
|                               |          |            | 24                       | 4      | 88    | 7      | 11     | 23   |
|                               | 5000     | +          | 25                       | 5      | 51    | 6      | 11     | 19   |
|                               |          |            | 34                       | 7      | 36    | 3      | 15     | 22   |



009614

Reverse Mutation Tests With and Without a Liver  
Metabolic Activation System (cont'd)

| Compound               | ug/Plate | S-9<br>Mix | Revertant Colonies/Plate |                  |                     |                    |                     |                     |
|------------------------|----------|------------|--------------------------|------------------|---------------------|--------------------|---------------------|---------------------|
|                        |          |            | WP2 <u>hcr</u>           | TA1535           | TA100               | TA1537             | TA1538              | TA98                |
| 2-amino-<br>anthracene | 10       | -          | 23                       | 8                | 179                 | 18                 | 23                  | 40                  |
|                        |          |            | 16                       | 11               | 201                 | 13                 | 21                  | 48                  |
|                        | 10       | +          | 98                       | 376              | > 3000              | 370                | > 3000              | > 3000              |
|                        |          |            | 79                       | 335 <sup>b</sup> | > 3000 <sup>c</sup> | 388 <sup>d</sup>   | > 3000 <sup>e</sup> | > 3000 <sup>f</sup> |
|                        |          | -          | 1672 <sup>a</sup>        | 315 <sup>b</sup> | 1024 <sup>c</sup>   | 10000 <sup>d</sup> | > 3000 <sup>e</sup> | 326 <sup>f</sup>    |
|                        |          |            | 2272                     | 358              | 1150                | 10000              | > 3000              | 296                 |

<sup>a</sup> AF-2 0.25 ug/plate

<sup>b</sup>  $\beta$ -propiolactone 50 ug/plate

<sup>c</sup> AF-2 0.05 ug/plate

\*Toxic

<sup>d</sup> 9-aminoacridine 200 ug/plate

<sup>e</sup> 2-nitrofluorene 50 ug/plate

<sup>f</sup> AF-2 0.1 ug/plate

00113